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CHAPTER 1.
Introduction.
1. PROINSULIN
1.1 General Introduction
Proinsulin is a protein hormone synthesised in the Beta cells of the Islets 
of Langerhans in the pancreas. It is the precursor hormone of insulin. 
The structure of insulin was described in 1953 by Sanger and Thompson 
as a protein hormone with two separate peptide chains, the A and B 
chains, linked by three disulphide bonds between cysteine residues, with 
a total of 51 residues.
Following this discovery, many models were proposed for insulin 
biosynthesis, but in 1967 Steiner et al, elucidated the mechanism by 
demonstrating the existence of a larger precursor protein which they 
called proinsulin. Using rat pancreatic tissue and human insulinoma 
tissue, radiolabelled amino acids were shown to be incorporated into 
insulin and another peptide one and a half times the size of insulin. 
Human proinsulin has 86 residues (Fig. 1).
Further work on the structure and physiological significance of proinsulin 
was delayed by the restricted availability of human proinsulin although a 
great deal of work was carried out using porcine and bovine proinsulins. 
The advances in biotechnology have more recently made possible the 
production of comparatively large quantities of purified human 
biosynthetic proinsulin by genetically engineering the DMA of the 
Escherichia coli bacillus (Frank et al, 1981).
1.2 Pancreatic Morpholoav
About 98% of the cells in the pancreas produce digestive enzymes. The 
other 2% of the cells are arranged in discrete 'islands' among the mass of 
the pancreas, called the Islets of Langerhans (Fig. 2). Four distinct
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Fig. 2. An Islet of Langerhans.
A or F c e l l s ( ^  Glucagon or pancreatic polyneptide 
D cel lsÇJ Somatostatin 
B cel 1 s(T) Insul in
Schematic representation of an is le t  of Langerhans 
shown distribution of glucagon, somatostatin, pancreatic 
polypeptide, and insulin containing cells . Is le t -ce l l  
types for which no positive function has yet been 
established are omitted.
( Modified from functional subdivision of islets of Langerhans and 
possible role of D cells by Orci and Unger, 1975).
polypeptide secreting cell types have been identified in the Islets. The a- 
cells secrete glucagon, which controls the maintenance of hepatic fuel 
production between meals. The p-cells, or Beta cells, secrete insulin. 
The D-cells secrete somatostatin, which plays a role in nutrient 
homeostasis, by acting as a neurotransmitter, a hormone, a 
neurohormone, and a parahormone to inhibit the release of growth 
hormone and regulate the secretion of other hormones, including insulin, 
glucagon, growth hormone thyrotropin and others. F-cells secrete a 
pancreatic polypeptide.
p-cells account for approximately 60% of the Islet endocrine mass and are 
found predominantly in the central area. A-cells, D-cells and F-cells line 
the periphery of the Islet in different areas, with the F-cells being found 
mainly in the head of the pancreas, and the A-cells in the tail. All the 
species studied so far have a heterocellular region which it has been 
suggested may have a functional role, perhaps as a pacemaker, since 
afferent blood vessels and autonomic nerves enter the Islet in this area. 
In humans, these extensions of the cortex area containing A and D-cells 
extend along the axis of the blood capillaries in the Islets, defining the 
tissue into microlobules, with heterocellular component always on the 
periphery.
1.3 Structure of Proinsulin
Studies in 1967 (Steiner et al) revealed a precursor of proinsulin with a 
molecular weight of 11500, and an additional 24 amino acids. Known as 
preproinsulin, this peptide can be detected at low concentrations in Islets 
of Langerhans, and is rapidly cleared by microsomal polypeptidases. 
The resulting proinsulin has a molecular weight of approx. 9000, and 86 
residues. The insulin A chain has 21 amino acids, the insulin B chain has
30 amino acids, and the connecting peptide has 35 amino acids. The C- 
peptide chain has 31 amino acids and is connected to the amino end of 
the A chain by a lysine and an arginine residue. 64 and 65, and to 
carboxyl end of the B chain by two arginine residues, 31 and 32. These 
two pairs of basic residues are lost during insulin synthesis (See Fig 1.) 
The C-peptide chain is considered to be crucial to the alignment of the A 
and B chains of insulin in the correct position of disulphide bond formation 
between the cysteine residues, thereby achieving the final tertiary 
structure of the molecule. Thus correct tertiary structure is determined by 
primary structure as dictated by thermodynamic hypothesis. If insulin Is 
denatured and then renatured by oxidation of these thiol groups and 
reformation of the disulphide bonds, correct insulin function and structure 
is not achieved as inappropriate disulphide bonds are formed. 
Denatured proinsulin with intact primary structure will reform correctly and 
can be subsequently cleaved to give active insulm.
Studies of various mammalian species have shown that the structure of 
insulin has been fairly well conserved through the evolutionary time span 
of most species, with porcine insulin being very similar to human insulin, 
varying only in one residue. This would suggest that insulin function 
depends to a large extent on the order of the residues.
Mammalian C-peptides have much wider variation and this is to be 
expected if the function of C-peptide is principally to achieve the correct 
tertiary structure proinsulin. One mole of proinsulin is therefore cleaved 
to secrete one mole of insulin and one mole of C-peptide.
1.4 Biosynthesis of Proinsulin
The gene coding for insulin in man is on the short arm of chromosome 
eleven (Overbach etal, 1981). The gene contains 1789 base pairs and is
longer than would be required to produce cytoplasmic mRNA coding for 
the precursor peptides of insulin. The newly transcribed mRNA is 
therefore modified before it is released into the cytoplasm of the Beta cells 
where It binds to the ribosomes of the endoplasmic reticulum and 
translation takes place.
The translation in vitro of the insulin mRNA results in a more complex 
preproinsulin form of the proinsulin hormone. With a molecular weight of 
11,500, it contains a 24 amino acid residue signal peptide at the NH2 
terminus. It has a short N-terminus region, usually containing charged 
amino acids and a sequence of hydrophobic residues, which facilitate the 
translocation of the newly transcribed peptide through the membrane of 
the rough endoplasmic reticulum (RER). Preproinsulin also contains a 
signal peptidase cleavage site at the C-terminus between the prepeptide 
and the propeptide. The sequence of this signal peptide Is quite 
conservative between eukaryotic and prokaryotic organisms. The 
prehormone is rarely detected in intact p-cells and it is thought that the 
presegment may be cleaved before the synthesis of the entire molecule is 
completed. (Robbins et ai 1984) As the preproinsulin is synthesized it 
rapidly folds and the disulphide bridges between the cysteine residues 
form. The signal peptide moves the preproinsulin into the cisternal 
spaces of the RER. A membrane bound signal peptidase removes the 
signal peptide, and the resulting proinsulin is transferred via the vesicular 
tubes of the RER to the peripheral elements of the Golgi apparatus where 
the vesicules fuse with the membrane of the cis-pole of the Golgi 
apparatus. This is an energy requiring process.
81.5 Conversion of Proinsulin to Insulin
After an hour or so, immature secretory granules are formed by 
vésiculation of the trans-pole of the Golgi apparatus. These vesicles 
have a single membrane and contain proinsulin proteolytic enzymes and 
zinc ions. As the vesicles mature, and move towards the periphery of the 
p-cells, proinsulin is converted to zinc insulin and C-peptide. The 
proinsulin is cleaved between residues 65 and 66 and between 32 and 
33 to produce diarginyl insulin by a trypsin-like enzyme which hydrolyses 
the bonds. A carboxypeptidase removes the arginine residues 31 and 32 
from the C-terminal and the B chain, and residues 64 and 65, lysine and 
arginine, from the C-terminal of the C-peptide chain.
The insulin molecules crystallize with the zinc ions and are released from 
the mature granules into the pancreatic vein by a mechanism of reverse 
pinocytosis. The pancreatic vein opens into the portal system, and the 
insulin traverses the liver before entering the systemic circulation. (Fig 3.)
1.6 Proinsulin in Serum
It can be seen from Fig. 3 that the conversion of the proinsulin to insulin 
can occur by a branched pathway, and different intermediates of 
conversion are found in p-cells and serum. It Is estimated that 3% of 
proinsulin escapes complete cleavage to Insulin in normal humans, and 
can be found circulating in the blood as intact and conversion 
intermediate forms. (Robbins et al, 1984). Kinetic analysis of proinsulin 
processing has shown preferential formation of the des-31,32 proinsulin 
to the des-64,65 proinsulin at the ratio of three to one. (Given et al, 
1985). The pancreatic tissue studies showed that normal human tissue 
did not contain any measurable quantity of the split proinsulins.
9FIG. 3. Conversion Intermediates of Proinsuiin
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C Arg 
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T
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suggesting that the carboxypeptidase removing the dibasic residues is in 
relative kinetic excess.
Proinsulin in serum is heterogenous. It has been estimated that the 
concentration of the insulin, proinsulin, 32,33 split proinsulin and 65,66 
split proinsulin in young male normal subjects is 20, 2.3, 2.1, and <1.0 pM 
respectively, at fasting level, (Sobey et al, 1989). At maximum after a 
glucose tolerance test these levels rose to 150, 9.9, 19.7 and an individual 
maximum for 65,66 split proinsulin of 3.8 pM. These assays 
demonstrated very high crossreactivities. The assay for intact proinsulin 
crossreacted 60% with 65,66 split proinsulin, and the 32,33 split 
proinsulin assay 84% and 60% with the intact and 65, 66 split proinsulins 
respectively. The low measured levels of 65,66 split proinsulin were 
taken not to interfere with the specificity of the assay for intact proinsulin. 
The assay did not distinguish between the split and the des (di-desamino 
derivative of the split form) proinsulins, so in accordance with reported 
findings in pancreatic tissue, the split forms may not exist in measurable 
quantity in serum. It would seem that of the reported 3% of unconverted 
proinsulin, very little is actually intact proinsulin, most being in the split 
32,33, or possibly des 31,32 forms.
Other intermediates have been reported from insulin gene mutations, and 
cases of familial hyperproinsulinaemia.
1.7 The Control of Proinsulin Secretion and Conversion to Insulin
A sensitive, and when required, rapid system of control of insulin 
synthesis is needed to respond to the changing levels of serum glucose. 
Itoh and Okanoto, (1980), have shown that translation of already 
transcribed mRNA coding for preproinsulin is increased in response to
11
short term regulatory demands, although altered rates of transcription of 
mRNA may play a part in long term response to physiological demand. 
There is less evidence for the control of the conversion of proinsulin to 
insulin. Orci et al, (1986), have suggested that the pH value of the 
vesicles pinched off from the Golgi apparatus may be crucial to enzyme 
activity and proinsulin processing. The vesicles gradually increase in 
acidity as processing takes place and the vesicle’s clathrin coat is shed.
1.8 Biological A ctiv itv_ j)i_  ProlnsiiUji_ and Its Co n ve r s I o n 
Intermediates
With the availability of biosynthetic human proinsulin, much work has 
been done to establish the biological activity of circulating proinsulin, (as 
intact and conversion intermediate proinsulin,) and its potency as 
compared with insulin. There is some discrepancy in the published 
literature, with values for binding and biological potency of proinsulin 
varying from 1 to 10% of native insulin. One group have used rat 
adipocytes and biosynthetic human proinsulin to show a binding potency 
of proinsulin of 11%. Kinetic studies attributed this decreased affinity to a 
decreased association rate rather than an increased dissociation rate. 
Biologic potency was assessed by measuring glucose transport as 10% of 
the activity of insulin, suggesting a close coupling between binding to 
receptors on the cell membrane and the membrane generated cellular 
response (Podlecki ef a /1984).
Other workers have reported values of 7%, (Cohen et al, 1985), and 8% 
biologic potency, 10% binding potency, (Revers et al, 1984). Another 
group using similar methods reported only a 1% receptor binding affinity 
but were unable to account for the discrepancy with other reported values.
12
The ratio of insulin metabolic clearance rate (MCR) to proinsulin MCR is
4.8 : 1. (Bergenstal et al, 1984), and this has been one of the reasons for 
much research into the efficacy of proinsulin as a therapeutic tool in the 
treatment of diabetes.
1.9  Froiosulin
It must be remembered in all estimates of the levels of proinsulin that 
different assays may be measuring different proinsulins. Work done by 
Madsen, Frank and Steiner, (1984) has identified the antigenic 
determinants recognised by human proinsulin specific monoclonal 
antibodies. One determinant, GS, is localised to the site of the linkage of 
the B chain to the C-peptide (Arg, Arg) at position 31,32, and a second 
determinant, Gn, is composed of residues in a three dimensional site 
located in regions 40 to 45, and 57 to 63. The spontaneous formation of 
this Gn determinant may play an important role in the formation of the 
tertiary structure of proinsulin through the correct disulphide bonds.
Gray et a l , (1987) report that the immunoreactivity of extracted pancreatic 
standard was found to be one hundred times higher than that of 
biosynthetic human proinsulin. Pure samples of split proinsulins 32,33 
and 65,66 reacted Similarly to pancreatic standard, and the reactivity of 
biosynthetic proinsulin was increased by reaction with trypsin, attributed to 
the production of partially cleaved proinsulins still retaining the C-peptide 
chain.
1.10 Proinsulin and Disease
The fasting basal levels of intact proinsulin and 32,33 split proinsulins in 
patients with non insulin dependent diabetes mellitus, (NIDDM) have 
been found to be higher than those of normal subjects, both in obese and
13
non-obese groups in both categories (Temple et al 1989). The 
percentage of proinsulin like molecules of the total insulin containing 
molecules was also found to be higher in the diabetic group, both obese 
and non-obese. Concentrations of 65,66 split proinsulin were too low to 
identify differences between groups. The responses of serum proinsulin 
following a glucose intake in patients with NIDDM and normal controls 
were not significantly different, although insulin and C-peptide responses 
were impaired in the NIDDM group. Deacon et al (1988) concluded that 
NIDDM is not associated with exaggerated proinsulin release in response 
to glucose compared with healthy subjects, but rather with normal release 
of proinsuiin but impaired release of insulin and C-peptide, suggesting a 
reduced ability at the post-translational stage to process proinsuiin to 
insulin. Yoshiota etal (1988) speculate on the release of proinsuiin from 
immature secretory granules in the glucose stimulated state in NIDDM. 
Work by Kitabchi (1977) shows that immunoreactive proinsuiin levels as a 
response to an oral glucose tolerance test are raised in diabetic subjects 
as opposed to normal subjects, and in obese compared with lean in both 
diabetic and normal groups.
In stress or exhaustion of the pancreas due to advanced age, obesity or 
disease, it would seem that proinsuiin secretion is increased, perhaps due 
to conversion enzyme deficiency or reduced serum clearance rates. 
Insulinomas are tumours of the Islet cells of the pancreas producing 
insulin at an inappropriate and usually excessive rate with regard to the 
demands of serum glucose regulation. Patients with insulinomas 
exhibited raised fasting serum proinsuiin levels even when the measured 
plasma glucose was within normal limits. In 88% of patients with 
insulinoma, the proinsuiin component of total immunoreactive insulin
14
exceeded 25%, and was up to 80% if the insulinoma was malignant. 
Pancreatic polypeptide may also be elevated (Sherman et al 1975, 
Hampton et al 1988). If insulin secretion is measured during an artificially 
induced state of hypoglycaemia, insulinoma patients will show impaired 
suppression of insulin secretion, and measurement of plasma proinsuiin 
during the suppression test should discriminate between differentiated 
and undifferentiated tumours, the latter giving rise to raised plasma 
proinsuiin in proportion to C-peptide, with more likelihood of malignancy, 
(Sherman et al 1975, Turner et al 1977).
Hypoglycaemia as a condition rather than as a result of mismanagement 
of diabetes with insulin or sulphonylureas, is rare. Diagnosis must rule 
out self-induced hypoglycaemia, or hormone deficiency or hepatic 
disease impairing gluconeogenesis. Familial hyperproinsulinaemia is 
associated with a coding mutation in the insulin gene, (Carroll etal, 1988). 
It was found that the hyperproinsulinaemia was the result of the secretion 
of proteolytically unprocessed mutant prohormone from the Islets of 
Langerhan via an alternative unregulated pathway. It has been shown 
that individuals with hyperproinsulinaemia from two unrelated families 
secreted similar or identical proinsuiin intermediates in which COOH- 
terminus of the C-peptide chain was extended by the Insulin A-chain, and 
from which the B-chain has been released by oxidative sulphitolysis, with 
the arg. 65 residue replaced by another amino acid. (Robbins et al, 
1984). Up to 90% of the serum immunoreactive insulin of these 
individuals had a molecular weight indistinguishable from that of 
proinsuiin and most showed normal glucose tolerance.
Patients with thyrotoxosis exhibit significantly raised plasma 
concentrations of proinsuiin, both fasting and during glucose tolerance
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tests. Insulin and C-peptide concentrations are not elevated. (Sestoft et 
al, 1981).
Patients with cystic fibrosis can show elevated proinsuiin levels in 
conjunction with impaired glucose tolerance, and it is suggested that the 
raised proinsuiin partly compensates for the relatively insufficient Insulin 
response, although no mechanism for this linkage is postulated. (Hartling 
etal, 1988). Following these findings, the same group (Hartling etal, 
1988) analysed fasting proinsulins in the serum of normal siblings of 
established IDDM patients and found that fasting proinsuiin was elevated 
in this group, whether or not the siblings were twins, but that fasting 
glucose and insulin were normal. This could represent a family trait, 
perhaps indicating p-cells more vulnerable to destruction, or maybe 
previous p-cell damage not leading to IDDM as yet. Insulin 
autoantibodies (lAA) have been demonstrated in patients with newly 
diagnosed IDDM before insulin treatment. It has also been shown that 
lAAs may be present in the serum months or even years before IDDM 
develops. It has been demonstrated that proinsuiin specific 
autoantibodies (PAAs) can be present in the serum of newly diagnosed 
IDDM patients before insulin administration, even in the absence of lAAs, 
and that the presence of PAAs indicates the involvement of insulin 
precursor molecules in the immune processes of IDDM. (Kuglin et al, 
1988).
A recent study measures insulin, proinsuiin and proinsuiin intermediates 
to determine any correlation between levels of these hormones in NIDDM 
subjects and cardiovascular risk factor, as it is known that there is a higher 
risk of cardiovascular disease in NIDDM. The study concluded that high 
concentrations of insulin-like molecules are associated with changes in
1 6
recognised cardiovascular risk factors in NIDDM, with 32,33 split 
proinsulin being related to diastolic blood pressure, (Nagi ef a/,1990).
1.11 ErQ,josulln and Obesity
There has not been a great deal of work done with the direct intent of 
establishing the relationship between obesity and the circulating levels of 
proinsulin and its intermediate forms. Peiras et al (1989) found that 
obesity and body fat distribution make independent and additive 
contributions to alterations in glucose insulin homeostasis. Temple et 
a/,(1989) report on the work done to measure the levels of insulin, 
proinsulin and proinsulin intermediates following an oral glucose load. 
The levels of intact and 32,33 split proinsulins were significantly higher in 
NIDDM patients than in controls, both in normal and obese groups. The 
reported figures show that intact and 32,33 split proinsulins were higher in 
the obese groups of both NlDDM’s and controls at basal levels. The 
percentage of proinsulin-like molecules, (proinsulin and its intermediates) 
of the total insulin containing molecules was significantly higher in the 
NIDDM obese and non-obese groups, both at basal level and 30 minutes 
after the glucose was ingested, but there was no difference between 
obese and non-obese groups of either controls or NIDDM subjects. This 
report and another paper by the same group, (Temple eta! 1990) suggest 
that previous studies of insulin may have over-estimated insulin levels 
due to crossreactivity with proinsulin-like molecules in the assays used.
1.12 Proinsulin as a Treatment for Diabetes
There has been much interest and research in recent years in the use of 
proinsulin as a treatment for the different types of diabetes. The 
availability of human biosynthetic proinsulin using recombinant DNA
17
technology (Frank etal, 1981), lead to clinical trials and studies to assess 
the efficacy and safety of human proinsulin as a treatment for diabetes. 
Studies in patients with NIDDM have shown that its hypoglycaemic effect 
is achieved mainly by suppression of hepatic glucose output, with little 
stimulation of glucose disposal by tissue uptake, and less resulting 
hypoglycaemia as compared with insulin. (Glauber etal, 1987).
In 1984, Berganstal ef a/conducted studies on IDDM patients comparing 
the administration of infused intravenous human biosynthetic proinsulin 
with insulin. They concluded that physiological levels of infused 
proinsulin are ineffective in maintaining euglycaemia in these patients, 
and that 13.7 times the steady state plasma proinsulin compared to insulin 
was required to maintain euglycaemia, estimating proinsulin as having 
7.3% the biologic activity of insulin. After the infusions were discontinued, 
the rise in plasma glucose was delayed significantly compared to insulin 
consistent with the much slower clearance rate of proinsulin. Bock and 
Quabbe, (1989), used human biosynthetic proinsulin successfully to 
control blood glucose in unstable IDDM patients with some evidence of 
improved stability. Another group report that biosynthetic insulin and 
proinsulin have additive but not synergistic effects on total body glucose 
disposal, (Revers et al, 1984). The biological activity of proinsulin des 
64,65 is now reported to be 200% that of insulin (B. Frank by personal 
communication).
It has been shown by Fineburg etal, (1987), that human proinsulin is a 
weak immunogen when used as the principal insulin agonist in insulin 
naive NIDDM patients. Proinsulin use did not significantly increase 
proinsulin specific antibodies and may reduce the formation of antihuman
18
insulin antibodies and the need for the concomitant therapy required with 
regular insulin administration.
The responses of serum proinsulin following a glucose intake in patients 
with NIDDM and normal controls were not significantly different, although 
insulin and C-peptide responses were impaired. Deacon etal, (1988), 
concluded that NIDDM is not associated with exaggerated proinsulin 
release, but rather with a normal release of proinsulin compared with 
insulin. This suggested a reduced ability at the post-translational stage to 
process proinsulln to insulin. Yoshiota et al, (1988), speculate on the 
release of proinsulin from immature granules in the glucose stimulated 
state in NIDDM. Many clinical trials to estimate the efficiency of proinsulin 
as a therapy for diabetes have been carried out. WauldhausI et al, 
(1988), concluded that proinsulin used as a replacement for basal insulin 
in patients with IDDM showed a 24% great efficacy over conventional 
insulin therapy (Ultratard), possibly due to reduced proinsulin clearance, 
or possible over-estimation of its unitage by the calibration process used. 
No antibody formation or proinsulin side effects were reported. Studies 
involving patients with NIDDM have shown that proinsulin is more 
effective than sulphonylureas in controlling fasting plasma glucose, but it 
is not so effective in controlling post prandial plasma glucose, (Pasmantier 
etal, 1988).
A review paper first published in 1988 and emanating from the research 
laboratories at Eli Lilly and Co., Indianapolis, USA., (Galloway et al, 
1992.), concludes that treatment of diabetes with human biosynthetic 
proinsulin had certain advantages as compared with insulin when 
assessed by pharmacological studies, but that unique efficacy was not 
demonstrated by clinical trials. One multicentre trial reported an
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increased incidence of myocardial infarction. With concern over safety 
factors Lilly suspended trials in 1988.
The use of proinsulin as a treatment would seem to be of questionable 
value.
2. IMMUNOASSAY FOR PROINSULIN
In view of the involvement of proinsulin in all the aforementioned clinical 
conditions, and possible use in therapy, it is obviously necessary to be able to 
measure serum proinsulin accurately and quickly. Assays for proinsulin must 
take into account the conditions for which they are developed. Earlier reported 
assays for proinsulin were measuring the hormone without any estimations of 
the relative ratios of intact to split proinsulins now known to exist in circulating 
serum.
Deacon etal, (1985) measure fasting proinsulin-like immunoreactivity, using a 
polyclonal antiserum in a radioimmunoassay, as 15pmol/L, with no insulin or C- 
peptide crossreactivity. Hampton et al, (1988), give a value of 6.7pmol/L for 
fasted normal subjects, and 14.2pmol/L for NIDDM patients, also using a 
polyclonal antiserum in a direct radioimmunoassay. Both these assays have a 
sensitivity of about 4pmol/L. An enzyme linked immunosorbent assay, (an 
ELISA,) measuring proinsulin with no crossreactivity with insulin or C-peptide at 
physiological levels was reported by Hartling efa/(1986). However this assay 
takes at least seven days to carry out.
Gray et al, (1986), report the use of monoclonal antibodies in 
immunoradiometric assays for proinsulin and the intermediate forms, 
demonstrating fasting levels of a maximum of 5.3pmol/L of intact proinsulin. 
Assays using monoclonal antibodies have been reported as being specific for 
intact proinsulin and 65,66 and 32,33 split proinsulins, (Sobey etal, 1989).
20
Although quite high crossreactivities are reported, use of the assays in 
combination allowed for measurement of the levels of insulin, proinsulin and the 
intermediate proinsulins to be made. It had been thought that incorrect 
estimations of insulin have been made in the past due to the inclusion of 
proinsulin intermediates in the measurement of insulin levels.
ELISA techniques offer a system which can be sensitive, very specific, robust 
and rapid, without the need for the use of radioactivity with its attendant 
disadvantages. Specificity of the assay is a major consideration when 
designing a proinsulin assay if it is required to distinguish between the different 
proinsulins in serum. Monoclonal antibodies are monospecific for a single 
antigenic determinant on an antigen, and as has been shown, their use can 
allow accurate measurements to be made of proinsulin in a radioimmunoassay, 
and their specificity should be exploitable in an ELISA system.
3. ANTIBODY MOLECULES
3.1 The Structure and Function of Immunoglobulins
Antibody molecules are globular proteins known as immunoglobulins, 
produced in response to the invasion of an organism by foreign material, 
e.g. proteins, carbohydrates, bacteria etc. The substance eliciting the 
immune response is called the antigen, and it may contain one or more 
antigenic determinants, small regions which are recognised as "foreign". 
Immunoglobulins are subdivided into five classes by certain structural 
features, size and charge, known as IgG, (immunoglobulin G), IgM, IgA, 
IgD and IgE. Some classes have further heterogeneity defined by minor 
differences.
It has been established that human beings are capable of producing at 
least a million different antibody structures, with a combining site for just
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one antigenic determinant, but all have a similar basic structure. 
Therefore one antigen with several antigenic determinants could elicit the 
synthesis of several different immunoglobulin molecules, or possibly 
different antibodies which recognise the same determinant, but with 
different affinities.
Rodney Porter (Porter, 1959, Porter, 1962) demonstrated that the most 
common immunoglobulin IgG, could be cleaved using papain into three 
fragments, each with a relative molecular mass of 50,000. Two fragments 
were very similar and had specific antigen binding properties, and were 
called Fragments antigen binding, or Fab regions. The third fragment did 
not bind antigen and was called the Fc region, (Fragment crystallisable). 
The fact that the region will form crystals shows that these regions are 
structurally homologous, and Fc fragments from different antibodies in the 
same class are virtually identical.
Gerald Edelmann (Edelmann, 1959, Edelman etal, 1960), using pepsin to 
digest the IgG molecule, made a similar fragment and a larger molecule of 
relative molecular mass 100,000, which suggested two Fab fragments 
joined together. He also showed that the IgG molecule was made up of 
two light and two heavy chains, relative molecular mass 25,000 and 
50,000 each, held by disulphide bonds. Rodney Porter then postulated 
the arrangement of the chains as shown in Fig. 4.
The N-terminal tips of the light and heavy chains form the antibody 
combining sites, and the hinge region allows flexible spacing between the 
two sites. This work won Porter and Edelman the Nobel Prize for 
Physiology in 1972.
Within the light and heavy chains of IgG, and also the other 
immunoglobulin classes, there are variable regions, which show greater
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Fig. 4. Immunoglobulin S t r u c tu r e .
Antigen Antigenbinding binding
H e a v y
P a p a in  s p lits  
P e p s in  s p lits
Hinge region
Variable
region
Constant
region
Complementarity
determining
segments
COOH COOH terminal
diagram m atic  structure fo r  Ig G .
The light chains (L )  are  d iv ided into domains V i  (variable  am ino ac id  sequence)  
and C l {constant am ino  ac id  sequence). The heavy chains ( H )  are  d iv ided into  
domains (var iab le  am in o  a c id  sequence) an d  C i f . C „2 , an d  C /y i. The antigen  
binding sites are V i . -  " H i n g e "  polypeptides in terconnect the dom ains . The  
positions o f  in ter- a n d  in tracha in  cystine bonds are shown.
From C. R. Cantor and P. R. Schimmel, Biophysical Chemistry, Part I, W. H. Freeman, San
Francisco, 1980.
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variation in the amino acid sequence at the N-terminals of both chains, at 
the antibody combining site. There are also constant regions in both 
chains where the residue sequence varies little.
The tertiary structure of the light and heavy chains is very important. The 
immunoglobulin molecule is divided into structural domains of p-pleated 
sheets stabilised by disulphide bonds. In the variable regions there are 
hydrophobic forces in operation conveying rigidity to this area for the 
conformation of the correct binding site. In the hinge regions there are 
proline residues known to allow conformational flexibility.
IgA is characterised by more disulphide bonds than IgG, and at different 
positions, a higher carbohydrate content and free -SH groups at C- 
terminals. IgM has an additional constant region and is usually found as 
a pentamer. IgD and IgE are found only in very low concentrations. The 
function of IgD is not really known. IgE is produced in allergic reactions 
which can damage healthy tissue, but may be a trigger for the 
inflammation which is an adaptive response to multicellular parasites, e.g. 
tapeworm.
Antibodies can themselves be antigens if used as such in a different 
species. All mammalian species investigated make the same classes of 
immunoglobulins as humans. The difference between immunoglobulins 
of the same class taken from different species are located mainly in the Fc 
regions, and the antibodies, in this case antiglobulins, are made to 
combine with this region.
3.2 Antibody Affinity and Avidltv
The forces binding an antibody to its antigen are electrostatic and 
hydrophobic forces, and hydrogen bonding. The strength of the binding 
between antibody and a monovalent antigen, called affinity, depends on
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these forces, as does the ease with which the complex will dissociate. 
This is a reversible binding reaction. Serum will contain a mixture of 
antibodies to probably several antigenic determinants on an antigen, and 
the total binding of the serum with the antigen is known as the avidity.
3.3 The Clonal Selection Theory of Antibody Formation
It is now known through research done in the 1950's that the combining 
site of a specific antibody is predetermined before it encounters an 
antigen, and that the pool of B-lymphocyte in the body contains at least 
one lymphocyte precommitted to recognise each one of 10 to 100 million 
different antigens. When a B-lymphocytes meets its predetermined 
antigen it reproduces itself by mitotic cell division, producing a clone of 
identical cells. These cells then differentiate into plasma cells and begin 
to synthesise and secrete antibody. This is the clonal selection theory of 
antibody diversity, from the work of MacFarlane Burnett (1959).
Some members of the clone differentiate into memory cells, which live for 
months or even years, and will replicate and produce antibody, thus 
providing a basis for more immediate response if the same antigen is 
encountered again. The basis of antibody diversity is genetic, contained 
in a pool of less than a thousand genes. These genes are rearranged by 
somatic recombination as the lymphocytes differentiate, giving each one a 
particular and peculiar combination of genes.
3.4 Monoclonal Antibodies
From the clonal selection theory, a clone of terminally differentiated 
lymphocytes produce a monospecific antibody in response to a single 
antigenic determinant on an antigen. Antigens may have several 
antigenic determinants and elicit a response from several lymphocytes
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producing several different antibodies to the same antigen. Therefore an 
antigen is injected into a selected species with the aim of producing 
antibody in the animals serum for use in assays of the original antigen in 
another species. The resulting antibody will probably be from several 
clones, producing a polyclonal serum when harvested from animal. It is 
not possible to culture B-lymphocytes in vitro to maintain a source of 
antibody supply.
In 1975 a breakthrough in technique was reported by Kohler and Milstein 
who had fused immortal mouse myeloma cell line with antibody producing 
lymphocytes from a mouse spleen to produce a hybridoma cell line. 
These cells can be cultured in vitro to produce a continuing supply of 
antibody specific for a single antigenic determinant on the antigen used to 
immunise the mouse from which the spleen lymphocytes were harvested. 
Cell lines can be frozen in liquid nitrogen and then recultured when 
further supplies of the cell line are needed.
Although certain antigens are more immunogenic in some species than 
others, the choice of species in which to raise the antibody has been 
limited because of the lack of suitable fusion partner myeloma cell lines 
which are not available. Intra-species fusions are now being done using 
lymphocytes and heterohybridoma fusion partners produced by first fusing 
mouse myeloma cells with peripheral blood lymphocytes. Some workers 
have used this technique to provide a source of long term production of 
high avidity monoclonal antibody in species of choice. (Groves et al, 
1987.)
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CHAPTER 2.
The Production of a Monoclonal Antibody to Human C-peptide.
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1 INTRODUCTION
1.1 Cell hybridization
The production of monoclonal antibody by hybridoma cells is based on 
the clonal selection hypothesis of Macfarlane Burnett (1959). Each 
mammalian lymphocyte cell has the potential to make an antibody which 
is monospecific, i.e. which will bind to a single determinant on an antigen. 
The constant region of the antibody chain may alter during differentiation 
of the lymphocyte clone, but the variable region remains specific. An 
antigen will elicit an immune response which is not monospecific, as 
many determinants on the antigen may be immunogenic to different 
lymphocytes.
Monospecific antibodies are secreted by a clone of terminally 
differentiated lymphocytes with a finite life span, which cannot be cultured 
in vitro. However tumours of these types of cells are found or can be 
induced in some mammals, and these myeloma cells can be readily 
cultured. If the myeloma cells can be fused with the antibody secreting 
lymphocytes, the resulting hybridomas can be cloned to select a clone 
grown from a single hybridoma (i.e. lymphocyte) secreting the required 
monospecific antibody. The hybridoma will have the antibody secreting 
properties of the lymphocyte and the immortal character of the myeloma 
cells.
1.2 Donor Lymphocytes
The lymphocytes chosen for fusion can be from the spleen or from 
peripheral blood. Spleen lymphocytes are obtained by sacrificing the 
previously immunised animal, this technique being more practical for 
small mammals such as mice or rats, and these animals have been
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extensively used in the development of the monoclonal antibody 
techniques in the past few years. Enough blood lymphocytes for a fusion 
can be obtained from a single bleed from larger mammals such as sheep, 
without the necessity for sacrificing the animal, and immunization of the 
animal with possibly expensive antigens could also provide useful 
polyclonal serum as well.
1.3 Myeloma Fusion Partners
From the work of Kohler and Milstein, (1975, 1976), it is known that to 
maintain antibody production in B lymphocytes differentiated in response 
to antigen stimulation, fusion should be between populations of cells from 
the same species and at the same state of differentiation. Kohler and 
Milstein derived an antibody secreting hybridoma from fusion between 
spleen B lymphocytes and a myeloma cell line. Success depends on the 
derivation and use of a myeloma cell line which has lost its ability to 
produce or secrete antibody.
One such cell line is P3/NS1/1 Ag 4-1, (known as NS1). This line does 
synthesize an immunoglobulin light chain, but does not secrete it. NS1 
was the cell line used by Kohler and Milstein (1975), and the one chosen 
for the murine/murine intraspecies fusions in this study. It is commercially 
available.
The choice of species to be used as donor for the B lymphocytes is limited 
by the availability of myeloma cell lines as fusion partners. Interspecies 
fusions have proved difficult, resulting in chromosome loss from one or 
other fusion partner affecting antibody production or the immortal character 
of the heterohybridomas. For the fusions with sheep peripheral blood 
lymphocytes in this study, a stable ovine/murine non antibody producing 
heterohybridoma cell line was used as the fusion partner. 
Heterohybridomas producing monospecific antibody have been reported 
using this cell line (Groves D.J. et al, 1987).
1.4 Selection of the hybridomas
It is necessary that parent cell lines can be selected against and 
eliminated in culture, particularly as the myeloma cells grow more strongly 
in culture than the hybridomas. The unfused spleen cells and any 
spleen-spleen hybrids are already terminally differentiated and will die 
after a short time in the culture medium. The most common method is to 
use a parent myeloma line which has been selected for its sensitivity to 
aminopterin which blocks one of the pathways leading to DNA synthesis. 
DNA can be synthesised in cells by two distinct pathways, the salvage 
pathway and the de novo pathway, (Fig. 1). The salvage pathway uses 
the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT) 
to synthesise the nucleotides inosine-5-phosphoribosyl (IMP) and 
guanosine-5-ribosyl (GMP) from the raw materials thymidine and
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Purine*
  HGPRT
salvage:--- Hypoxanthine-------- ^  Inosinic acid ribose phosphate
(6-oxypurine)
HGPRT
Guanine  ^  Guanine acid-ribose phosphate
(6-aminopurine)
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small moiecules — ^ Inosine *  DNA
monophosphate Adenosine  y RNA
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Xanthosine
monophosphate
Guanosine
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salvage: Deoxythymidine  ^  Thymidine monophosphate\ DNA 
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de novo: deoxyuridlne monophosphate
Î
small molecules ________________^  deoxycytidine monophosphate
Figure L  Nucleic acid biosynthesis - The basic biochemical pathways for the biosynthesis 
of purines and pyrimidines are shown. The pathways available to the cell include 
the de novo and salvage routes.
HGPRT = hypoxanthine guanine phosphoribosyl-transferase 
TK = thymidine Kinase
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hypoxathine. DNA and RNA are then synthesised using HGPRT and 
thymidine kinase (TK). The myeloma line used for fusion lacks the 
enzyme HGPRT and is unable to synthesise DNA by the salvage pathway. 
In culture, the newly fused cells are provided with thymidine and 
hypoxanthine in the culture medium, and the hybridomas can synthesise 
DNA by the salvage pathway because they have the ability to produce 
HGPRT conferred by the lymphocyte fusion partner. The de novo 
pathway is blocked by the addition of aminopterin to the culture medium 
(Fig. 2) and the unfused myeloma cells are unable to synthesise DNA by 
either pathway, and they cannot survive.
1.5 Fwsogenic Agents
In early fusion experiments (Harris, 1965, Cotton and Milstein, 1973, 
Kohler and Milstein 1975, 1976, Margulies et al, 1975), ultra violet 
inactivated Sendai virus was used to promote fusion between 
lymphocytes and myeloma cells. The rate of fusion however was found to 
be only slightly higher than naturally occurring spontaneous fusion 
(Yelton et a l , 1981), which happens at a frequency of 1 x 10®-1Q7 cells. 
Polyethylene glycol (PEG) was first applied in fusion of mammalian 
somatic cells by Pontecorvo etal, (1975) and has been widely used since. 
This is the agent used in this study. Electric field induced fusion was first 
used by Zimmerman etal, (1981) and Vienken and Zimmerman (1981!) 
used his method in a mouse/mouse fusion which eliminated the need for 
long term biochemical selection and lengthy cloning procedures.
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de novo Blocked by Aminopterin
GMP
TMP
HGPRT
guanine
hypoxanthine
GMP
TK
deoxythymidine »  TMP
DNA, RNA
Figure 2, Biochemical basis of the use of HAT supplemented medium - There are two 
biosynthetic routes to DNA and RNA, the de novo and the salvage pathways. 
Aminopterin, a folic antagonist blocks the de novo pathway and hence only the 
salvage pathway may be utilised. If the cell possesses the raw materials (thymidine 
and hypoxanthine) and the enzymes required it will be capable of nucleic acid 
synthesis. The mouse myeloma line NSI lacks the HGPRT and thus is unable to 
make DNA by either pathway in HAT supplemented medium and therefore dies.
HAT = hypoxanthine aminopterin thymidine
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1.6 Cloning
Cloning techniques are carried out as soon as producing wells can be 
identified by assay. Antibody-producing cells can be quickly overgrown 
by non-producers, and good lines can be lost by delay in cloning, (Galfre 
and Milstein, 1981).
The technique of limiting dilution, when cell suspension is diluted to a 
theoretical average of one cell per well, will ensure that good hybridomas 
are not lost by overgrowth, and should ensure that clones are truly 
monoclonal, (Coding 1986).
Following the Poisson distribution (Letkovits and Waldman, 1979),
f(o) = e
where f(o) is the fraction of wells containing no clones À is the average 
number of clones required per well. When X = 1, then f(o) = 0.37. 
Therefore 37% of the wells would show no growth to achieve a 
reasonable possibility that any well with growth would contain only a 
single clone. Single clone wells can then be selected visually with the 
aid of a microscope with some certainty, but the cloning procedure with 
appropriate screening techniques should be repeated to ensure that cells 
are truly monoclonal.
In practise, the technique of cloning is delicate. If the cells are all seeded 
in the culture plates at 0.3 cells/well, hybridomas may be lost as the cells 
tend not to grow so well at low densities. Mouse hybridomas have a 
tendency to clump together and they may be pipetted together whatever 
the theoretical cell density. If cells are seeded at a higher cell density it 
cannot strictly be called cloning, and resulting hybridomas should be 
recloned more than once. This is usually done anyway to ensure 
monoclonal character. Higher density cloning does help to maximise the
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chance of hybridoma survival. The original well containing the 
hybridomas selected for cloning should also be maintained until 
successful cloned cultures are established.
Cells can of course be seeded out at varying densities. Final proof of 
monoclonal character must be assessed by procedures to determine the 
antibody class and affinity, epitope analysis or even karyotyping of the 
hybridomas.
1.7 Immunization of Lymphocyte Donors
The immune response is evoked in vertebrates by material recognised as 
foreign to the organism. The level of immunogenicity of a given molecule 
is dependent upon its tertiary structure, the types of antigenic sites on the 
molecule, and its size. Molecules of less than 5000 daltons are not very 
immunogenic. C-peptide is a relatively small biological molecule, 3250 
molecular weight (m.w.) and it has a loose tertiary structure which does 
not elicit a strong immune response.
Therefore the C-peptide used in the immunization programme prior to 
fusion of the donor lymphocytes with the myeloma cell line is conjugated 
with large protein molecules chosen for their size and antigenic character. 
Keyhole limpet haemocyanin, 5x10® m.w., and egg albumin 45,000 m.w. 
were used. The large conjugated molecule will readily be recognised as 
foreign by the animal's immune system.
The polyclonal serum from the immunized animal will contain antibodies 
to antigenic determinants on the carrier proteins, C-peptide and perhaps 
the chemical bridge between the two. Screening techniques will select 
the hybridomas secreting antibody to C-peptide.
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When immunizing mice, a small amount of BCG vaccine can be included 
in the innocula. This substance will be very antigenic, and will have the 
effect of stimulating the immune system to elicit a better response
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2. METHODS AND MATERIALS
2.1 Materials
BDH Chemicals Ltd., Poole, Dorset.Polyethylene glycol 
All laboratory reagents.
Beckton Dickinson (Vacutainer Systems), France.
Lithium heparinised Vacutainers.
Bibby Steriiin, Staffs., UK
Sterile universels, pipettes.
Caibiochem-Behring Corp., La Jolla, Ca 92037.
Keyhole limpet haemocyanin.
Difco Labs., UK.
Trypan blue dye.
Eli Lilly, Indianapolis, USA.
Biosynthetic human C-peptide
Biosynthetic human proinsulin and intermediates.
Gibco Life Technologies, Palsiey, UK.Culture medium and additives 
Fetal calf serum.
Dr. D. Groves, U. of Surrey.
Ovine-murine heteromyeloma.
B. Morris, U. of Surrey.
Non-UIcerative Freunds adjuvant.
Nunclon, Denmark (supplied via Gibco).
Sterile plastic culture vessels
Nycomed (UK) Ltd., Birmingham.
Lymphopaque.
Sigma Chem. Co. Ltd.
Egg albumin 
Gluteraldehyde.
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2.2. Preparation of the Immunogen
110mgs keyhole limpet haemocyanin (0.022 pmoles) dissolved In 4 ml 
distilled water was added to 200|xl of 0.25M gluteraldehyde solution. 
O.Smgs (0.153 pmoles) biosynthetic human C-peptide was dissolved in 
1 ml distilled water and added to the keyhole limpet haemocyanin/ 
gluteraldehyde solution.
The mixture was dialysed against distilled water for 4 days at 4°C a further 
5 ml of distilled water was added and aliquots containing 50pg/ml and 
25|xg/ml C-peptide were freeze dried.
A second conjugate was prepared by the same method using Img (0.307 
jimoles) biosynthetic human C-peptide and 2mg (0.044 pmoles) egg 
albumin, and freeze dried in aliquots of 200pg/ml C-peptide.
The method was taken from a Thesis to the University of Surrey, Dr. S.M. 
Hampton, (1983)., conjugating C-peptide and egg albumin. The 
quantities for the first conjugation were calculated from this method on a 
molar ratio basis.
2.3 Immunization of Mice
Two months prior to fusion, 4 female Balb/c mice were immunized by intra 
peritoneal injection (IP) with lOpg C-peptide conjugated to keyhole limpet 
haemocyanin emulsified in non-uIcerative Freunds adjuvant, (B. Morris). 
28 days later the mice were boosted with the same preparation. After a 
further 28 days, and four days before fusion, the mice were boosted again 
with 400|ig C-peptide conjugated to egg albumin, and on the third, 
second and penultimate day with 200pg of C-peptide. All injections were 
given IP.
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2.4 Immunization of Sheep
The sheep chosen for donor lymphocytes had been previously immunized 
for 2-3 years with C-peptide for the purpose of developing and producing 
polyclonal antisera to this protein.
One sheep previously immunized with proinsulin was boosted with 
proinsulin for fusion of peripheral blood lymphocytes to produce a 
monoclonal antibody to proinsulin.
Polyclonal antisera had been successfully raised in these animals. The 
sheep were boosted by intra muscular injection in the leg at eight sites 
five days before fusion, using a total of 275|Lig C-peptide/egg albumin 
conjugate.
2.5. Preparation of Lymphocytes
2.5.1 Preparation of culture media.
Culture medium used throughout the fusion procedures was RPMI 
with L-glutamine, plus Iml/IOOmIs penicillin/streptomycin solution 
and 1ml/100mls sodium pyruvate, referred to as RPMI. For cell 
culture RPMI is prepared with 10% fetal calf serum (PCS), and 
contains 2 ml/IOOmIs x50 HAT solution, (hypoxanthine, 
aminopterine and thymidine), immediately following fusion or x50 
HT once the hybridomas have been selected.
2.5.2 Counting the Cells
Spleen lymphocytes are not readily visible under a light 
microscope, and counting can be facilitated by the use of the stain 
trypan blue. A 0.05ml aliquot of the spleen cell suspension is 
added to 0.3 ml 0.9% ammonium chloride solution. This causes 
the lymphocytes to swell and become more easily seen, and lyses 
the erythrocytes. Trypan blue will stain the dead cells, and the live
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lymphocytes can be counted, taking into account the dilution factor. 
A mouse spleen will yield in the order of 10^ lymphocytes and all 
are used for the fusion.
2.5.3 Feeder Laver
A non immunized mouse of the same strain as the immunized mice 
was killed by cervical dislocation, drenched in 70% alcohol, and 
the spleen removed employing sterile procedure. The spleen was 
transferred to a sterile petri dish containing 2 ml RPMI culture 
medium and taken to a laminar flow cabinet where all further work 
was carried out. Every care was taken to exclude the possibility of 
bacterial, fungal or viral contamination at this and every 
subsequent stage of the fusion programme, as infection can be 
difficult, if not impossible, to eradicate and can result In the loss of 
valuable cultures.
Using a sieve, the spleen was gently teased out to release the 
spleen cells. The cell suspension was gently sucked up and 
released to further break up the spleen tissue. The suspension 
was made up to 10 ml with RPMI at 37°C, was placed in a sterile 10 
ml centrifuge tube and allowed to stand for 10 min to allow the 
clumps to settle. The suspension was poured off into another tube 
and centrifuged for 5 min, the supernatant was poured off, and the 
pellet of cells was resuspended in 10 ml RPMI. The cells were 
counted and diluted with RPMI so that the suspension contains 1.5 
X 10® cells/ml, and plated out in 24 well culture plates 1 ml/well. 
The plated were incubated at 37°C in a 5% CO2  in air, humidified 
incubator. All cell cultures are Incubated under the same 
conditions.
39
2.5.4 Preparation of Mouse Spleen Donor Lymphocytes
A preparation of spleen lymphocytes from an immunized mouse is 
prepared according to the technique for the preparation of the 
feeder layer cells, and the cells are counted.
2.5.5 Preparation Of Sheep Peripheral Blood Lymphocytes 
100 ml of blood was collected from the jugular vein of the 
immunized sheep using a bleeding cup and lithium heparinised 
vacutainers. The tubes were agitated gently to help prevent 
coagulation until the blood could be processed.
The tubes were cleaned in the laboratory with 70% alcohol and all 
further processes carried out in a laminar flow cabinet as for the 
spleen lymphocytes.
The blood was diluted 50 : 50 v/v with phosphate buffered saline 
solution pH 7.6 (PBS), also containing lithium heparin.
4 ml of blood/PBS was layered onto 3 ml Lymphopaque in sterile 
10 ml centrifuge tubes avoiding mixing the layers, and the tubes 
were centrifuged at 2100 rpm for 30 min. This resulted in a red 
blood layer at the bottom of the tubes, a clear layer at the top and a 
thin cloudy layer containing the lymphocytes In the middle. This 
cloudy layer was removed using sterile pasteur pipettes and 
collected in 10 ml centrifuge tubes over 5 ml Hanks buffer salts with 
added heparin and spun again for 10 min. The resulting pellets 
were resuspended in 2 ml of the same Hanks solution and spun for 
a further 10 min.
The pellets were then resuspended In 10 ml RPMI at 37°C in a 
tissue flask. At this stage the cells may be incubated overnight for 
fusion the next day:
The cells were counted before fusion.
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2.6 Preparation of the Myeloma Fusion Partner
2.6.1 N S rs
About 7 days before the planned fusion, NSI cells stored in liquid 
nitrogen at -190°C are picked up from the frozen state by thawing 
the tubes as quickly as possible in a warm water bath. The cells 
are suspended in RPMI and centrifuged. The pellet of cells is 
resuspended in RPMI and the cells are cultured until required for 
fusion. It is necessary to have available for fusion 1 : 5 ratio 
myeloma to lymphocyte cells, and the NSI's should be in an active 
logarithmic growth phase with greater than 95% viability on the 
day of fusion. Aim for 10^ cells to be available as fusion partners 
if required.
2.6.2 Ovine/Murine Heterohvbridomas
The cells were supplied frozen in liquid nitrogen and are treated in 
the same way as NSI's, and prepared for fusion accordingly.
2.7 Fusion Procedure
2.7.1 Preparatory Work
Ensure that all equipment is available and where necessary 
sterilised. Pick up and culture the fusion partner cells. Prepare 
and plate out the feeder layer on the day before the fusion. 
Prepared a 50% solution of autoclaved polyethylene glycol 6000 
(PEG) in RPMI and store it at 4°G. Once the mouse has been 
sacrificed the fusion must proceed without delay, or weeks of 
preparation will be lost.
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2.7.2 Fusion Technique
All the media for the fusion are prepared and kept at 37°C.
A suspension of spleen lymphocytes is prepared from the 
immunized mouse and the cells are counted and suspended in 10 
ml RPMI.
The NSI fusion partner cells are counted and sufficient cells in the 
ration 1:5 with the spleen lymphocytes are spun down and 
resuspended in 10 ml RPMI.
The lymphocytes and NSI's are mixed together and spun down. 
The supernatant is carefully poured off and the pellet of cells 
gently tapped to loosen it. The centrifuge tube is placed at an 
angle of 70°C in a water bath at 37°C.
0.8 ml of PEG solution is added to the cells over a period of 1 
minute, stirring gently and continuously.
Over the next 5 minutes 10 ml RPMI is added, stirring 
continuously.
The suspension is spun down, the solution drained off and the 
pellet is resuspended in RPMI by releasing 10 ml of medium 
directly at the pellet, stirring only mildly. The resulting cell 
suspension is made up to 100 ml with RPMI containing 10% PCS 
and 4 ml/100 ml HAT (diluted to 2 ml/100 ml when added to feeder 
layer). The cell suspension is added 1 ml/well to the 24 well 
culture plates previously prepared with 1 ml/well feeder layer.
The plates are incubated as before and looked at every day to 
observe progress and check for contamination.
On the day of fusion control wells are established containing only 
NSI's. Grown in culture medium containing HAT the cells should
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all die and by about day 5 they will be dead. When this cell death 
is observed in these wells, it is safe to continue culturing the 
hybridomas using medium containing HT only. On day 5, 1 ml of 
the medium is removed from the wells and replaced with fresh 
medium containing HT.
Hybridomas will be observed growing in the wells, quite often 
around the edge of the wells. After about 10 days supernatant 
from wells with any significant hybridoma clones in them can be 
screened for the presence of antibody to the antigen used for 
immunization. Satisfactory screening techniques should have 
been established by this stage.
Any positive wells should be cloned immediately to prevent 
overgrowth of worthwhile clones. All wells with hybridomas 
should be counted to record fusion efficiency for the particular 
technique used for possible comparison with further fusions or 
modification of the technique to improve fusion efficiency if 
necessary.
2.7.3 Sheep Heterohvbridoma Fusion
The technique used for the fusions of ovine/murime 
heterohybridoma fusion partner cells with sheep peripheral blood 
lymphocytes was essentially the same as that detailed above. 
The lymphocytes were collected and prepared on the day of the 
fusion. 107 lymphocytes were fused with 2 x 1 0 6  
heterohybridomas, using all available lymphocytes. The cells 
were plated out in 96 well culture plates over a feeder layer.
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2.8 Screening Techniques
2.8.1 Enzyme Linked Immunosorbent Assay (ELISA1 for
Specific Antibody
Polyvlnylchloride microtitre plates were coated with Ipg/m l 
biosynthetic human C-peptide in bicarbonate/carbonate buffer pH
9.6, 200|il/well, incubated overnight at 4°C.
The plates were washed three times with phosphate buffered 
saline pH 7.6, containing 0.1% gelatine and 0.05% Tween 20 
(PBSGT).
The supernatant from the cultured hybridomas was added to the 
plate 200p,l/well and incubated for two hours at 37°G.
The plates were washed as before.
Donkey anti mouse IgG labelled with horse radish peroxidase 
(HRPO) was added to the plate 200pl/well at an initial dilution 
1:5000 in PBSGT and incubated for 1 hour at 37‘^ G.
The plates were washed as before.
The substrate o-phenyienediamine was added to the plate, 150pl/well
and incubated for 30 minutes. The reaction was stopped with 
50pl/well of 1M hydrochloric acid and the absorbance read at 
492nm.
2.8.2 ELISA for Mouse laG
Using buffers and washing as before;
Polyvlnylchloride microtitre plates were coated with hybridoma 
supernatant and incubated for 2 hours at 37°G.
Donkey anti mouse IgG enzyme label at an initial dilution 1:5000 
was added to the wells, 200)Lil/well, and incubated for 1 hour at
37°G.
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The substrate o-phehylenediamîne was added to the plate 150pl/well, 
and Incubated for 30 minutes at 37°C. The reaction was stopped 
with SOpl/well of 1M hydrochloric acid and the absorbence read at 
492nm.
2.8.3 ELISA for Mouse laG Classes 
Using buffers and washing as before:
Polyvlnylchloride microtitre plates were coated with donkey anti 
mouse double antibody 40pg/ml, 200pg/well, and incubated for 2 
hours at 37°C.
Monoclonal C6  ascites fluid initial dilution 1:50 in PBSGT was 
incubated overnight at 4°G.
Sheep polyclonal anti mouse IgG classes antibodies were added 
to the plate initial dilution 1:5000 in PBSGT, 200|iI/well, and 
incubated for 2 hours at 37°G.
Donkey anti sheep enzyme labelled double antibody initial 
dilution 1:5000 was added to 200p.l/well and incubated for 2 hours 
at 37°G.
The substrate o-phenyienediamine was added to the plate, 150pl/well, 
and incubated for 30 minutes at 37°G. The reaction was stopped 
with 50pl/well of 1M hydrochloric acid and the absorbance read at 
492nm.
2.8.4 Radioimmunoassay for Specific Antibody
200|il hybridoma supernatant, 2 0 0 pl iodine 125 labelled G- 
peptide and 200pl 0.04M phosphate buffer containing 0.5% 
bovine serum albumin (BSA) were added to plastic Lp3 tubes. 
The tubes were vortexed and incubated overnight at 4°G.
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The next day lOOpI donkey anti mouse IgG double antibody and 
700^1 4% PEG solution were added to the tubes to phase 
separate, and the tubes were vortexed and incubated for 2  hours 
at 4°G.
The tubes were centrifuged for 30 minutes at 2500 rpm, aspirated 
and counted on a gamma counter.
2.8.5 Immunocvtochemistrv
Normal human pancreatic tissue and insulinoma tissue, 
impregnated with wax, was sliced and mounted on glass slides. 
The sections were dewaxed in xylene and taken through 
decreasing concentrations of alcohol from 100% down to 50% and 
washed in running water.
The sections were immersed in blocking agent H2 O2  methanol for 
1 0  minutes and washed in running water.
The tissue sections were incubated for 30 minutes in 1% non 
immune serum in 25mM Tris saline buffer pH 7.6. The serum is 
taken from the species in which the second antibody was raised, 
in this case donkey.
The sections were then covered with G6  G-peptide monoclonal 
antibody ascites fluid initial dilutions 1:50, 1:100, 1:200, diluted in 
1% non immune serum, PH4 insulin monoclonal antibody initial 
dilution 1 :2 0 0 , and a negative control monoclonal antibody initial 
dilution 1:200. The slides were incubated overnight in an 
humidified incubator at 4°G.
The slides were washed carefully in Tris saline buffer using a 
wash bottle, rinsing and leaving for 1 0  minutes and then repeating 
the process.
46
The slides were dried carefully and 200|Lil/slide donkey anti mouse 
IgG initial dilution 1:1000 in Tris saline buffer with 1% normal 
donkey serum (NDS) as before was added to the sections and 
Incubated for 40 minutes.
The rinsing with wash bottle was repeated.
The sections were incubated in chromogen double antibody, 125 
mg in 300 ml citric acetate buffer pH5.0, plus 200pl 100 volume 
30% H2 O2  for 3 minutes at 20°C.
The sections were rinsed in running water for 10 minutes and then 
in distilled water for 1 minute.
The slides were dipped in haematoxylin stain for 2  minutes. If the 
staining had been too dark, the slides could have been 
differentiated in acid alcohol for a few seconds to remove some of 
the stain. The slides were then rinsed in running water for 10 
minutes.
The sections were dried by moving them back through the alcohol 
concentrations to 1 0 0 %, and then into xylene.
The slides were mounted using DPX and glass cover slips, taking 
care not to allow the tissue to dry out.
2.9 C loning
Following the identification of wells containing antibody producing 
hybridomas by screening techniques, cloning was carried out without 
delay. The cells were counted and a suspension of 5  x 1 0  ^cells in 5 ml 
was prepared. The cells were then diluted in RPMI as prepared for fusion 
containing 20% PCS and HT, to cell densities of 25, 5, and 0.5 cells/ml. 
The suspensions were plated out in 96 well culture plates, 200pl/well over 
feeder layer to promote growth of hybridomas at these low cell densities.
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One plate was used for each cell density. The plates were cultured for 1 2  
- 14 days and monitored with a light microscope. Any wells which 
appeared to have a single clone were screened for specific antibody 
production, and positive wells were expanded to 24 well plates, and on to 
culture flasks. It may be necessary to repeat cloning to ensure 
monoclonal character, although other techniques can be used to confirm 
this.
2.10 Freezing
It is vital at all stages to preserve positive cell lines. Cells were frozen 
from expanded positive clones as soon as sufficient cells were available 
from expanded cultures. If possible it is wise to freeze cells from the 
original wells to ensure survival of any positive cell line, and to ensure 
against loss of cells by infection or accident. Cells in log phase growth 
were counted, spun down and resuspended in cryopreservative medium, 
90% PCS with 10% dimethylsulphoxide (DMSO), at a count of 10® 
cells/ml. 1 ml of suspension/vial was placed in labelled plastic freezing 
vials. The vials were frozen at -2 0 °C for 1 - 2  hours, -80°G for a further 1 - 2  
hours, and then placed in liquid nitrogen at -190°G.
2.11 Ascites fluid
The fluid obtained from an induced ascitic tumour in mice contains very 
high titre monoclonal antibody compared with the supernatant from the 
hybridoma cultures.
Older Balb/c mice, about 1 5 - 1 8  weeks, were injected intraperitoneally 
with 0 .5m l/m ouse  Pristane. g days later each mouse was injected at the 
same site with 0.5 ml non ulcerative Preunds adjuvant (B. Morris) and the
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next day with 1.5 x 10® hybridoma cells in lOOpI PCS. The resulting 
tumour may be tapped or the mouse sacrificed and the tumour drained.
2.12 Fusion Schedule
Over a period of sixteen months two fusions using mouse spleen 
lymphocytes and NSI's, and seven fusions using sheep peripheral blood 
lymphocytes and ovine/murine heterohybridoma fusion partner cells were 
carried out. Three fusions used a Suffolk sheep immunized with C- 
peptide, three a Soay sheep immunized with C-peptide and one a Suffolk 
sheep immunized with proinsulin. The Balb/c mice were immunized with 
C-peptide.
3. RESULTS
3.1 Fusion Efficiency
All but one fusions were successful, producing hybridoma clones in an 
average of one well in eight. The last fusion performed using a Soay 
sheep to provide the peripheral blood lymphocytes and fusing with a 
murine/ovine heterohybridoma partner produced very few hybridoma 
clones and no positive antibody secreting cells.
One fusion was lost due to failure of the incubator, and one fusion became 
contaminated. As it had no promising cell lines, it was scrapped to avoid 
the spread of bacterial contamination to other work.
3.2. Mouse Spleen Lymphocyte Fusions 
Fusion 1.
1 X 1Q7 spleen lymphocytes (all available cells) were fused with 2 x 10® 
NSI's. The fusion mixture was plated out in four 24 well plates. Wells 
with hybridomas could be seen by the change in the colour of the medium
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from pink to straw yellow as the acidity changed. Hybridomas were 
observed using a light microscope in approximately one well In eight after 
a few days.
Twelve days after fusion, all wells were screened by ELISA, with RPMI 
containing PCS used as a negative control.
Four wells positive for C-peptide antibody were identified. The 
absorbence readings are given in Table 1, below.
Table 1. %.Absorbance OP 492nm above negative control in C- Peptide ELISA
% above control
RPM110% PCS 100%
Supernatant 1 1 2 2 %
Supernatant 2  217%
Supernatant 3 179%
Supernatant 4 (3/0/27) 165%
After expansion and growth of these wellsonly 3/0/27 remained positive 
and was cloned by limiting dilution.
One positive and stable cell line was established, known as C6 . This 
antibody was positive when screened both by ELISA and RIA. These 
hybridoma cells were used to innoculate mice for ascites fluid production, 
and the cell line was frozen and successfully re-established.
The ascites fluid was screened in an ELISA to establish the class of 
antibody present. The results are shown in Table 2 , below.
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Table 2. ELISA for antibody class with C6
antibody class O.D. 492nm
lgG1 0.48
lgG2 A 0.66
lgG2B 1.23
lgG3 2.4
IgM 2.2
IgA 0.7
The imunocytochemistry demonstrated binding to the [3 cells in the Islets 
of Langerhans by the insulin monoclonal antibody used as a positive 
control, but the C6  antibody showed only a generalised binding to the 
pancreatic tissue.
Although the ascites fluid was positive for C-peptide antibody in the 
screening ELISA and RIA, it did not work when tried in initial efforts to 
develop a sandwich ELISA for proinsulin, which was the purpose for 
which it had been produced.
The results from these efforts at characterisation of the antibody were 
inconclusive. The sheep anti mouse immunoglobulin classes antibodies 
used were polyclonal, and therefore probably not completely specific. 
Further cloning and repeated characterisation, including perhaps 
electrophoresis, would be necessary to establish true monoclonal 
character of this antibody.
Because at this time it was necessary to proceed with the effort to develop 
a specific proinsulin ELISA, and C6  did not work in the assay as seen at 
that time, stocks of 06 were frozen for possible future continuation, and 
further fusions to produce C-peptide monoclonals were carried out. It
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was not considered worthwhile at that stage to expend further time and 
money on the C6  antibody.
Fusion 2.
The second mouse fusion produced six initially positive wells, but 
antibody production was not sustained. Wells were screened by ELISA, 
and OD readings of more than twice the negative control reading of 0.44 
were taken as positive. Only one well continued antibody production 
after the wells were expanded, but this was not sustained.
3.3 Sheep Peripheral Blood Lymphocyte Fusions 
Fusion 1.
The first heterohybridoma sheep fusion used 2  x 1Q7 lymphocytes with 4 x 
1 0 ® ovine/murine heterohybridoma fusion partners. There were 
hybridomas in one well in nine, and seven initially positive wells were 
expanded onto feeder layer. However antibody production was lost after 
about two weeks. The wells were screened by RIA and the results are 
shown in Table 3, below.
Table 3. % above negative control in RIA of supernatant
% above control
RPMI 10% PCS 1 0 0 %
Supernatant 152 235%
Supernatant 649 298%
Supernatant 474 250%
Supernatant 665 356%
Supernatant 332 306%
Supernatant 229 252%
Supernatant 200 258%
Total Counts 4235
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These wells were expanded without delay, but antibody production was 
lost.
Fusion 2.
The next sheep fusion used blood from the same sheep as the first, eight 
weeks later, and without further immunization boosting. The fusion 
efficiency was one in nine wells, and 3 positive clones could be identified 
by ELISA. The results are shown in Table 4.
Table 4. % Absorbance OD 492nm above control in C-Peptide ELISA
% above control
RPMI 10% PCS 100%
Supernatant 428 308%
Supernatant 138 175%
Supernatant 118 237%
The hybridomas continued to grow well but antibody production declined.
Fusion 3.
A Soay sheep was the lymphocyte donor for the next fusion, immunized 
as detailed in the fusion methods, (as were all further fusion donors). 
80 xIO® lymphocytes were fused with 15 x 10® heterohybridoma cells as 
before. This fusion produced twenty positive wells at the initial screening, 
with counts per minute (cpm). levels of between two and four times the 
negative control. Twelve wells were expanded. However once again 
antibody production was not sustained.
53
Fusion 4.
A different Soay sheep was used for the next fusion. Ten positive wells 
were identified and eight wells proceeded to cloning but once again it did 
not prove possible to maintain a cell line with sustained antibody 
production.
As reported earlier, three other fusions were performed without resulting 
positive wells. One had very few initial hybridomas, and two were lost 
due to contamination or equipment failure,
4. DISCUSSION
The success of the fusion technique depends on several factors. The 
availability of rapidly dividing antigen-stimulated p lymphocytes, with fusion 
partner myeloma cells in log phase growth with 90% viability, is all important, 
(Hudson and Hay, 1980). The immunization programme was designed to 
maximise the animals response to the antigen, and the lymphocytes were 
harvested 4 days after the final boost to obtain the cells in rapid mitosis rather 
than at the time of maximum response in terms of antibody production expected 
at day 7 - 8 .  It has also been suggested by Steiner and Eisen (1967) that high 
affinity antibody becomes more likely as the immune response matures, 
because only cells with high affinity receptors are able to bind sufficient antigen 
from the decreasing supply to produce further cell divisions and provide 
dividing cells for successful fusion. Therefore an extended immunization 
schedule should improve the chances of developing high affinity monoclonal 
antibodies.
It is vital for fusion success that the fusion technique is correctly carried out. 
The methods followed in these fusions were essentially those described by 
Goding (1986). The concentration of the PEG, and itepurity and pH value are all
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important factors. Temperatures must be controlled. The ratio of lymphocytes 
to fusion partner cells is important. Sterile procedure must be maintained at all 
times. In all but one of the fusions in this project healthy hybridoma clones were 
produced in an average of one well in eight. Only one event of contamination 
was recorded, and appeared to be the result of general contamination within 
the hybridoma laboratory.
The numbers of wells initially producing antibody was not high, but the 
screening techniques were identifying positive clones. It seems likely that the 
problem stemmed from the poor immunogenicity of C-peptide in most mammal 
species. Although the structure of C-peptide does vary more between species 
than does that of insulin, nevertheless it is a very small molecule in biological 
terms and is probably not very antigenic in the species used for donor 
lymphocytes. Efforts to overcome this problem by conjugating the antigen to 
large immunogenic molecules have not been very successful in this case.
The major problem was the lack of stability after fusion of antibody producing 
hybridomas and heterohybridomas. Although most of the cell lines initially 
chosen for expansion and cloning after screening thrived under the culture 
regime, the antibody producing capacity was quickly lost in most cases. Rapid 
cloning avoided the problems of lost antibody producing lines by overgrowth. 
The only cell line (C6 ) frozen down and recovered for culture after a period of 
six months grew well and continued to produce antibody. Cell hybrids have a 
tendency to lose chromosomes, and this process can result in loss of antibody 
production. Even with great attention to all known factors affecting stability, it 
should be expected that 50 - 70% of initially positive wells will be lost, (Goding 
1986). Failing lines can sometimes be saved by extensive recloning and 
selections of possible stable lines.
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In a falling culture the non-producing cells will be stronger and will overgrow 
producers if cloning is not undertaken. Cells must be maintained in 
exponential growth. Culture medium should be replenished since lack of 
nutrients will result in chromosome loss. The stability of hybridomas is not well 
understood but careful technique can support antibody producing cells and 
minimise the effects of lack of stability. In this project few hybridomas initially 
producing antibody were identified and only one cell line proved stable through 
cloning and freezing.
The production of a C-peptide monoclonal antibody had been considered 
desirable for use in a sandwich ELISA to measure proinsulin. When C6  ascites 
fluid was used in sandwich assay for proinsulin it was not possible to produce a 
standard curve using proinsulin at physiological levels. This might have been 
due to the tertiary structure of proinsulin making the C-peptide section of the 
molecule unavailable for binding with the antibody.
Although some success had been achieved at this stage of the project, it was 
thought that further effort and expenditure was probably not justified in terms of 
the likelihood of success in producing in the time available a monoclonal 
antibody to C-peptide which could be used in an immunoassay for proinsulin.
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CHAPTER 3.
The Development of an Enzyme-linked 
Immunosorbent Assay for Intact Human Prolnsulin.
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1. INTRODUCTION
There is at the present time a great deal of interest and some current research 
in the physiological and biochemical significance of the production and 
circulating levels of proinsulin and its conversion intermediate forms. Assays 
available to date are mostly radioimmunoassays, some using monoclonal 
antibodies, and have been reported as being specific for intact proinsulin and 
its intermediates at fasting levels.
Radioimmunoassay has certain drawbacks inherent in the production, storage 
and disposal of the radioactive tracer. This project was designed to develop an 
enzyme-linked immunosorbent assay, (ELISA), for intact proinsulin which would 
be quick and robust, and yet sensitive to normal fasting levels. One ELISA 
reported has a low level of sensitivity of 1.2 pmol/L, but takes 7 days to perform, 
(Hartling et al, 1988). For clinical purposes a much faster assay is necessary.
At the outset of the project it was hoped that a direct sandwich ELISA could be 
developed using a monoclonal antibody to C-peptide, perhaps as the coating 
antibody, and an antibody to insulin as the first antibody, and in this way to 
achieve an assay specific for proinsulin. The possibility of a monoclonal 
antibody to proinsulin was also considered. It did not however in the time 
available prove possible to develop C-peptide monoclonals that would work in 
the assay.
The final assay developed is specific for intact proinsulin only. It uses an 
insulin monoclonal as a coating antibody, and a sheep polyclonal antibody to 
human biosynthetic proinsulin as the first antibody. The assay has negligible 
crossreactivity with insulin, C-peptide or the proinsulin intermediates. It takes 
about 24 hours to complete, including an overnight incubation stage, and is 
accurate to 1.67 pmol/L. It has good correlation with another established 
method, and has acceptable validation figures. It could prove to be a useful
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tool to estimate levels of intact proinsulin, and could be used in conjunction with
other assays to establish ratios of intact to intermediate proinsulins in serum.
1.1 The Th&Qry...flf-El(SA
The initial coating antibody or antigen is immobilised onto a solid phase. 
Standard dilutions and samples of the test antibody or antigen are 
incubated with the immobilised coating phase, and after washing, the 
second antibody labelled with enzyme is incubated with the antibody- 
antigen complex and binds to a second eiptope. Further washing is 
followed by incubation with the enzyme substrate. The enzyme reaction 
product is directly proportional to the concentration of the antibody or 
antigen in the standards or samples (Nakamura et al, 1986). The flow 
chart, Figure 1, illustrates the steps followed in an indirect non-competitive 
ELISA.
One of the main problems when developing a new ELISA is to eliminate 
as much as possible any non-specific binding at different stages in the 
assay, while at the same time maximising the specific binding. The 
binding qualities of the solid phase are very important. The different 
microtitre plates commercially available may bind any given coating 
substance with very varied results, and temperature sensitive edge wells 
and batch variations may affect inter-assay results.
Following the coating stage, an incubation with buffer containing proteins 
e.g. gelatine or bovine serum albumin (BSA), may help to block any 
protein binding sites still available on the solid phase.
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FIGURE 1. PROINSULIN ENZYME-LINKED IMMUNOSORBENT RSSRV PROTOCOL.
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The choice of coating and wash buffers may also help to reduce non­
specific binding.
The antibodies chosen for the assay need to demonstrate high affinity and 
specificity for the antigen, with low non-specific binding. When 
conjugated to the enzyme of choice for the label stage of the ELISA, the 
antibody should retain all or most of its affinity and the enzyme activity 
should not be affected.
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2. METHODS AND MATERIALS
2.1 .e.ufML,ao.d... Reagent Solutions
1 . 0.15M Phosphate buffered saline solution (PBS) pH 7.4.
Sodium chloride 8  grams
Di-sodiumhydrogen orthophosphate 2.9 grams
Potassium chloride 0.2 grams
Potassium di-hydrogen orthophosphate 0.2 grams
Distilled water to 1 litre.
2. Wash buffer PBS with gelatine and tween 20 or tween 80. 
One gram of gelatine and 0.5 ml tween to 1L PBS
PBSGT
3. Blocking buffers.
To 100 ml PBS, add 100 mg: gelatine
BSA
polypeptide
to give 1 % solutions.
4. Casein buffer pH 7.6
Tris/HCI pH 7.6 1.2 grams
Sodium chloride 9 grams
Casein 0.5% w/v 5 grams
Thiomersal 0 .0 2 % w/v 0 . 2  grams
Distilled water to 1 litre
5. 1 .OM bicarbonate/carbonate pH 9.6 coating buffer.
Sodium bicarbonate 5.88 grams
Sodium carbonate 3.18 grams
Distilled water to 1 litre
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6 . 0.025M Citrate/phosphate substrate buffer. 
Citric Acid
Disodium hydrogen phosphate 
Distilled water to 1 litre.
5.22 grams 
7.1 grams
7. Enzyme substrate
Substrate buffer 
0 -phenylenediamine
Hydrogen peroxide 30% solution
75 ml
30 mg (1 tablet) 
30|xl
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2.2 Materials
Aldrich (Gillingham, Dorset, UK.)
Dimethyl sulphoxide
Amersham International (Amersham, UK.)
Biotin streptavidin peroxidase complex 
Amerlite
Blozyme Laboratories Ltd. (Gwent, UK.)
Horse radish peroxidase
British Drug House Ltd. (Pooie, Dorset, UK.)
All chemicals not otherwise listed (Analar quality.)
Boeringer Mannheim (Mannheim, Germany.)
3,3% 5,5’ Tetramethylbenzidine
Cllfmar Associates (University of Surrey, Guildford.)
1000A amlnopropyl porous glass beads.
Cuno Inc. (USA)
Zeta Prep 60 mm Disk DEAE
Dynatech Laboratories (Billingshurst, UK.)
Disposable polyvlnylchloride flat bottom microtitre plates and Immulon 2  
flat bottom microtitre plates.
May and Baker Ltd. (Dagenham, UK.)
Sodium chloride
Medical International Ltd. (London, UK.)
Visking Dialysis tubing
Sigma Chemical Company Ltd. (Pooie, Dorset, UK.)
Bovine serum albumin 
30 mg. tablets
o-phenylenediamine dihydrochloride 
human serum albumin.
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2.2.1 Antiserum
Purified sheep anti-human proinsulin antiserum was supplied by 
Dr. S. Hampton, University of Surrey. It was produced for 
radioimmunoassay (Hampton et al, 1988) using biosynthetic 
human proinsulin kindly donated by Dr. Bruce Franks, (Eli Lilly and 
Co., Indianapolis, In, USA.) by method detailed in Hampton et al 
(1988).
The coating antiserum used in the first stage of the assay was a 
mouse monoclonal antibody to human insulin, In the form of ascites 
fluid, generously donated by the Scottish Antibody Production Unit, 
Carluke, Lanarkshire, Scotland, (batch No. ld4.G5.H8.F9). 
Although it is preferable to use an immunoglobulin fraction rather 
than whole ascites fluid to avoid competitive binding or interference 
from other proteins in ascites fluid, there was only a limited amount 
of ascites available to the project, and purification was not an 
option.
2.2.2 Standard
The standard used in the assay was biosynthetic human proinsulin. 
A small quantity was weighed on a Kahn microbalance and 
dissolved in 0.05M sodium phosphate buffer pH 7.4 containing 
0.5% human serum albumin which prevented the proinsulin from 
sticking to the vial, and added bulk. Aliquots containing 10 ng/vial 
werelyophilized and stored at -20°C.
2.2.3 Charcoal treated serum
Serum was collected from volunteers after an overnight fast, pooled 
and mixed with activated charcoal, 2 0 g/1 0 0 mls, and stirred 
overnight at 4°C. The supernatant after centrifugation at 1600g for
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15 minutes was filtered through a Zeitz filter Grade HP/KS (H. 
Erban Ltd., Suffolk), and aliquots were stored at -20°C until 
required.
2.3 Preparation Qf the Enzvme-labelled Antibody
2.3.1 (a1 Antiserum Purification
4 ml of donkey anti sheep antiserum from an animal immunized 
with Fc fragment of sheep IgG antibody was added to an affinity 
purification column, prepared by mixing activated porous silica 
(Clifmar Associates Ltd., University of Surrey, UK.) with sheep IgG 
in buffer and stopping the reaction with sufficient glycine to make a 
1M solution. The column, (0.8 x 6  cm), was equilibriated with 0.1 M 
phosphate buffered saline pH 7.5. The column was mixed and 
rolled and washed through with at least 20 ml of 0.15M phosphate 
buffered saline pH 7.4 (PBS).
4 ml of 0.1 M glycine solution adjusted to pH 2.2 with concentrated 
hydrochloric acid was added to the column and mixed and rolled 
for 10 minutes. The solution was collected from the column in 
aliquots of 1 ml. A further 2 ml of glycine solution was passed 
through the column and collected.
The protein content of the aliquots was measured and the solution 
dialysed against bicarbonate/carbonate buffer pH 9.6 at 4°G 
overnight. The column was washed with, and stored in, PBS buffer 
containing 0 .0 2 % w/v thiomersal.
2.3.2 (b) Enzyme Activation
40 mg horse radish peroxidase (HRPO) was weighed in a 1:1 ratio 
w/w with the affinity purified antibody (5 ml. 8  mg/ml). The HRPO 
was dissolved in the minimum amount of distilled water possible to
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avoid dilution of the eventual label when prepared. Sodium 
periodate was dissolved in distilled water, (0 . 2 1  g in 1 0  ml) to make 
0 . 1  M solution. 1 . 0  ml sodium periodate solution was added to the 
HRPO solution and mixed for 30 minutes on a roller. The solution 
was dialysed overnight against sodium acetate buffer, (0 .3 g in 2  
litres), pH adjusted to 4.4 with acetic acid, at 4°G. The activated 
enzyme was then added to the affinity purified antibody and mixed 
for two hours on a roller.
The reaction solution was then mixed with ethanolamine solution 
for one hour. The resulting solution of enzyme-labelled donkey 
anti sheep Fc fragment was dialysed against PBS thiomersal buffer 
overnight at 4°G and stored at 4°G until required.
2.3.3 (c) Labelled Antibody Purification
The newly prepared labelled antiserum proved to contribute an 
unacceptably high level of background interference to the assay 
and it was necessary to purify it using gel filtration. A gel was 
prepared using G2 0 0  superfine Sephadex, dry bead diameter 40- 
1 2 0 i)m with a fractionation range for peptides and globular proteins 
of molecular weight 5,000 - 60,000. The gel was prepared using 
PBS thiomersal buffer as before, with an approximate bed volume 
ml/g of 30 - 30. 5 grams of Sephadex with 2 0 0  ml of buffer was left 
to swell for 4 days at 4°G. After warming to room temperature, the 
gel was poured into a column ( 2  x 2 0  cm) and washed through with 
PBS.
7 ml of sample were added to the column and 30 x 1 ml fractions 
were collected starting from when the sample was added to the 
column, and the fractions were assessed in the ELISA.
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2.4 Assay Development
Throughout the following optimization procedures, certain factors 
remained constant. 200 pi. of reagents, 150 pi of substrate solutions, 
and 50 pi of 2.5M H2 SO4  were added to the wells in all assays. All 
plates were washed three times on a Titertek S8 / 1 2  automatic plate 
washer, (Flow laboratories, Rickmansworth, Herts), and tapped inverted 
on absorbent paper to remove any remaining buffer. A Dynatech 
Multiwash hand wash (Dynatech, Billingshurst), was used if casein buffer 
was used. Plates were Incubated at 37°C in a most chamber unless 
otherwise stated.
2.4.1 Optimization of washing and coating buffers
Soft plates were coated with insulin monoclonal antibody (F9) as 
above, initial dilution 1:2000, in 0.1 M bicarbonate/carbonate buffer 
(pH 9.6), or 0.15M phosphate buffered saline pH 7.4 (PBS), and 
incubated for 2  hrs.
The plates were washed in PBS containing 0.1% w/v gelatine if 
coated in 0.1 M bicarbonate/carbonate buffer and 0.5% w/v casein 
buffer, pH 7.6, if coated in PBS. Proinsulin standards at 215, 107,
53.5, 26.75, 13.38, 6.67, 3.34,, 1.67 pmol/L diluted in wash buffer 
and in 50 : 50 v/v buffer and hormone free plasma were added to 
the wells in duplicate and incubated overnight at 4°C in a moist 
chamber. The plates were washed and DEAE purified sheep 
antihuman proinsulin antiserum (batch No. HP/S/1313/1 ID (see 
section 2.4.5) was added to the wells diluted 80 pg/ml in wash 
buffer and incubated for 2 hrs. After washing, donkey anti sheep 
IgG HRPO labelled antiserum was added to the wells 1:10000 
initial dilution in wash buffer and incubated for 2 hrs. After a last
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wash, o-phenylenediamlne hydrochloride (OPD) substrate was 
added to the wells and Incubated for 30 minutes. The substrate 
was made with 30 mg OPD in 75 ml 0.025 citrate phosphate buffer, 
with 30 \i\ of 30% hydrogen peroxide. The reaction was stopped 
with 2.5M sulphuric acid after 30 minutes, and the optical density 
read at 492nm on a Titertek plate reader linked to a plate reading 
program on an Amstrad 1430.
2.4.2 Optimization of plates
The assay was carried out as above using bicarbonate/carbonate 
coating buffer and PBSGT wash buffer made with either Tween 20 
or Tween 80. The plates were both polystyrene and 
polyvinylchloride plates.
2.4.3 Optimization of monoclonal coating antibody
Using PBSGT as the wash buffer, and the assay as above, the 
mouse anti-insulin monoclonal was compared with two other 
mouse anti-insulin monoclonals, known as PH4 and PH5, (Scottish 
Antibody Production Unit), all as ascites fluid, and diluted at 1:1000 
to 1:16000. The labelled antibody was donkey anti sheep Fc 
fragment HRPO conjugate used at 1:16000.
2.4.4 Optimization of blocking agents
Following the coating stage, a blocking stage was added to reduce 
non-specific binding. PBS buffer containing 1 % bovine serum 
albumin, 1% gelatine or 1% polypeptide, casein buffer or PBSGT 
both as before, were incubated in the wells for one hour.
2.4.5 Optimization of polyclonal antiserum
Using the assay as before and including a blocking stage 
incubating PBSGT for 1  hour, three sheep polyclonal antisera.
69
(HP/S/1313 ID, HP/S/1313 V 13, and HP/SC2 IV  C) were 
compared with the one used so far. Small samples were purified 
by DEAE ion exchange chromatography, using a Zetaprep disc. 
2 ml of antiserum was diluted with 18 ml 0.01 M phosphate buffer 
and passed through the disc, eluted with further buffer and 
collected in 5 ml fractions. The absorbance of the fractions was 
read on a spectrophotometer at 280nm and fractions containing the 
immunoglobulin were pooled, read again and then diluted in the 
assay at 320,160, and 80 jxg/ml.
The antiserum was then optimized for incubation time and 
concentration. Dilutions of 40, 80 and 160 |o,g/ml. were incubated 
for 1, 2 and 3 hours.
2.4.6 Optimization of HRPO labelled antibody
The donkey anti sheep Fc fragment label was used in the assay as 
before diluted to 1:6000, 1 2 0 0 0  and 18000, and incubated for 1 , 2  
and 3 hours.
2.4.7 Optimization of the substrate
The assay was completed using OPD substrate as before, 
compared with 3, 3’, 5,5', tetramethylbenzidine (TMB) * 100 of 
stock solution containing 20 mg of TMB dissolved in 1 ml of 
dimethyl sulphoxide was added to 2 0  ml of substrate buffer with 1 0  
(.il of 30% hydrogen peroxide. Amerlite chemiluminescent 
substrate was also tried in the assay, and the plates read on a 
chemiluminesence reader.
2.4.8 Biotin avidln amplification system
Instead of the HRPO labelled antibody, biotin conjugated with 
donkey anti sheep IgG was incubated in the wells for 2  hours, initial
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dilution 1:20000 in wash buffer. Strepavidin biotin peroxidase 
complex, initial dilution 1 :1 0 0 0 , was incubated for one hour, and 
then TMB and OPD substrates were added as before.
This system provided three substrate binding sites for each 
molecule of biotin conjugated antibody bound, thus theoretically 
amplifying the colour signal by x 3 .
2.5. Assay Procedure
A Dynatech 96 well disposable polyvinyl microtitre plate was coated with 
mouse monoclonal to human insulin diluted in bicarbonate/carbonate 
buffer at an initial dilution of 1:2000, (200 pl/well) and incubated at 37®C for 
2  hours in a moist chamber.
The outside wells of the plate were not used as there has been found to be 
some variation in the readings from these wells, thought to be due to 
temperature differences. The plate was then washed three times on an 
automatic plate washer using PBS buffer containing 0.01% gelatine and 
0.05% Tween 20 (PBSGT). 200 pi of wash buffer was added to each well 
and incubated at 37°C for one hour in a moist chamber.
After washing again, samples were added to the plate in duplicate, 100 
pI/well with 100 pl/well of wash buffer, and incubated overnight at 4°G. 
Standard curves were added to each plate in the range of 1.67 - 430 
pmol/ 1  biosynthetic human proinsulin dissolved in charcoal stripped 
human serum, 1 0 0  pl/well with 1 0 0  pi of wash buffer.
Each plate also had quality control wells. Sufficient quality control 
aliquots were prepared for the duration of the project for maximum 
standardisation.
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After washing as before, 200 pi of polyclonal proinsulin antiserum, was 
added to each well diluted in wash buffer to 80 pg/ml, and incubated for 2  
hours at 37°C in a moist chamber.
The plate was washed, and incubated as before for a further 2  hours with 
200 pl/well of donkey anti sheep Fc fragment enzyme-labelled antibody 
diluted in wash buffer (initial dilution 1 :1 2 0 0 0 ) in a moist chamber.
After washing, 150 pi of orthophenylenediamine (OPD) solution was 
added to each well and incubated for 30 minutes at 37°C. OPD is the 
substrate for the horse radish peroxidase enzyme and the reaction is 
characterised by the production of a yellow colour. The reaction was 
stopped with 50 pl/well of 2.5M sulphuric acid, and the colour density read 
on an automatic plate reader at 492nm.
2.6. Samples - Collection and Storage
Samples used were venous blood collected from normal subjects after an 
overnight fast. The blood was placed in lithium heparin tubes, mixed and 
then immediately spun in a refrigerated centrifuge. The plasma was 
collected and stored in aliquots at 20°C till required.
Some patient samples were used, (courtesy Dr. S. Hampton), with known 
high serum proinsulin as measured by radioimmunoassay, (S. Hampton et 
a/, 1988), for comparison and correlation. Samples came from patients 
with insulinomas, or following glucose stimulation.
2.7. Validation of the Assay
The recovery of human biosynthetic proinsulin from serum from a normal 
fasting volunteer was measured over the range 6.7 - 215 pmol/l.
Parallelism between the standards and endogenous proinsulin was 
established by comparing the curve of the standards with the curve of a
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sample with high endogenous proinsulin serially diluted with charcoal 
stripped plasma.
Crossreactivity was established in the assay by including standard curves 
of intact proinsulin from 107 pmol/L to zero, C-peptide from 310 nmol/L to 
zero and insulin from 75 nmol/L to zero. Porcine and bovine insulins and 
proinsulin intermediates split 32,33, des 31,32, split 65,66, des 64,65, split 
56,57 and split 57,65 were all assayed in the range 10700 pmol/L to zero. 
(All proinsulin fragments kindly donated by Dr. Bruce Frank).
The effect of insulin on the intact proinsulin standard curve was 
established by including 1500, 750 and zero pmol/L insulin in buffer (100 
pl/well) in a standard curve 53.5 - zero pmol/L (100 pl/well). This assay 
was run at different temperatures and at different pH values. Interassay 
and intra-assay variations were established using quality control standards 
of intact proinsulin at 215, 107 and 53.5 pmol/L in normal human serum.
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3. RESULTS
3.1 pp tirni;gat!Qn of washing and cogting-b uffgrs
The use of bicarbonate/carbonate coating buffer and PBSGT wash buffer 
gave the better result in terms of sensitivity at low concentrations of the 
standard, with a greater difference between the high and low readings 
over the range of standards used. The development of the assay 
proceeded using this combination of buffer solutions. (Fig. 2 )
3.2 Optimization of plates
The level of non specific binding was reduced on both hard and soft plates 
by the use of Tween 20. There was no difference in the sensitivity of the 
assay at low standard concentrations on hard or soft plates using Tween 
2 0  and it was decided to proceed with soft plates.
3.3 Optimization of monoclonal coating antibody
The anti-proinsulin monoclonal PH5 did not perform well in the assay, with 
low binding giving low readings and poor sensitivity. The anti insulin 
monoclonal PH4 was slightly better than the anti insulin monoclonal F9 as 
used so far in the assay development. The monoclonal PH4 would have 
been the antibody of choice, but it subsequently transpired that this 
antibody had proved difficult to produce as ascites fluid, and it was unlikely 
to be available in any usable quantities. It was decided to proceed using 
the anti-insulin monoclonal antibody F9 which gave acceptable binding 
and good sensitivity In the assay. An initial dilution of 1:2000, incubated 
for 2  hours at 37°C gave an acceptable result, (Fig. 3).
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3.4 Optimization of blocking agents
The use of wash buffer PBSGT gave the best combination of low non 
specific binding and sensitivity, and the assay proceeded using a one hr. 
blocking stage following the coating antibody. (Fig. 4).
3.5 Optimization of polyclonal antiserum
Although all four polyclonal antisera tested worked in the assay and one 
showed good sensitivity at low levels of standard concentration, only the 
antiserum used so far (batch No. HP/S/13131 ID) had acceptable levels of 
non specific binding, the other three being very high. The dilution of this at 
sop.i/mi for an incubation time of two hours gave an acceptable 
combination of sensitivity and low non specific binding. Although an 
incubation time of three hours improved the difference between the 
readings of the highest concentrations of standard and zero, the difference 
was not worthwhile in view of the extra time involved as 80p,l/ml for 2  hours 
produced an acceptable result (Fig. 5a-f).
3.6 Optimization of HRPO labelled antibody
A dilution of 1:12K and incubation time of 2 hours gave the best 
combination of minimal non specific binding with good sensitivity over the 
standard range (see Fig. 6 a-c).
3.7 Optimization of the substrate
The use of TMB increased the levels of background colour in the assay 
and it was decided to proceed with OPD (Fig. 7). Although the standard 
curve in this assay is not good, it was considered sufficient for the purpose 
of the development of the assay.
The use of chemiluminescent substrate did not improve the assay.
77
CD■O
CDC
m 2  O  O
( 0«I-»c
0 )U)
<
D )C
oo
m
O)
UL
œ SCÛ .co
.
( u i u ^ e t ’) e o u e q jo s q v
78
Fig. 5a
Prolnsulin Antiserum HP/S/1313 V 13
Ec
CMo>
0)oc
<0
o(0SX<
1.15-
1.05-
0.95-
320 ug/mi 
160 
80
0.85 d
0.75-
0.65
0 10 20 30
Pro insu l in  (pm ol /L )
0>ocraja
o(0sx<
Fig. 5b
Prolnsulin Antiserum HP/S/1313 V 13
2 .0-1 320ug/mi
160
80
1.8  -
1.4-
0.8 -
0.6
0 1 0Pro insu i in 20(pmol /L ) 30
CMo>
0>uc
CO
o
(0JQ<
Fig. 5c
Prolnsulin Antisera HP/S/C2 IV
1.6 n
320ug/ml
160
80
0.8
0 10 20 30Proinsulin (pmol/L)
Ec
CM
O )
0)uccoJ3Oco.o<
Ec
CMO)
0)
ÜccoJ3i
ocoja<
79
Fig. 5d 1 hour
1 4  Prolnsulin Antiserum HP/S/1313 IID
1.2 -
1.0 -
0 .8 -
0.6 - 160 ug/ml 
80 
400.4-
0.2 -
0.0
1 1 0 100 1000
Pr oinsu l in  (pm ol /L )
FIg.Se 2 hours 
Prolnsulin Antiserum HP/S/1313 IID
1.0 -
0.8 -
0.6 -
160 ug/ml 
80 
40
0.4-
0.2
1 1 0 01 0 1000
Pro insu l in  (pm ol /L )
FIg.Sf. 3 hours.
Prolnsulin antiserum HP/S/1313
Ec
CMO)
1.5-
1.0 -ouc
COjQ 0.5 - 160 ug/mlo
COxt< 0.0 - 40
-0.5
1 10 100 1000
IID
Proinsulin (pmol/L)
8 0
Fig. 6a. HRPO label dilutions. 1 Hour.
Ec
CMO)'t
ucfOja
ov>
<
1.0 -
0.5 -
0.0
1 1 0 100
6K
12k
18k
P ro insu l in  (pm ol /L )
Fig. 6b. HRPO label dilutions. 2 Hours.
£c
CMo>
oucfOJ3OMja<
2
1
6k 2hrs
12k
16k
0
1 1 0 1 00
Pro insu l in  (pm ol /L )
Fig.6o. HRPO label dilution. 3 Hours.
£c
CMo>
Ooc
CD
JQO(0ja<
1.4 -
1.0 -
0.8 -
6K
12K
18k
0.6 -
0.4-
0.2 TTl'l"'.
1001 1 0
Proinsulin (pmol/L)
8 1
0 )
<0 en
(0
S I3
w
co
( 0N
E
CL
O
O) r■—  CDUL ■ CVJ p 00d COd
ooo
oo
oEQ.
_  O
3
0 )c
Ô
V .
CL
( u u i u 3 6 t ^ )  a a u e q j o s q v
82
3.8 Biotin avidln amplification system
The background levels of colour were too high using this system with 
either TMB or OPD as the substrate for the strepavidin biotin preoxidase 
complex. The amplification of the signal was not sufficient or necessary to 
compensate for the raised backgrounds or the extra time step added to the 
assay. (Fig. 8 ).
3.9 Standard Curve
The standard curve used in the assay measured a range of 430 - 1.67 
pmoi/L of biosynthetic intact human proinsulin. The limit of sensitivity was
1.67 pmol/L, as defined by two standard deviations from zero. (Fig. 9).
3.10 Validations
Precision. The intra-assay coefficient of variation as measured from the 
quality controls was 1 % at 215 pmol/L, 10.3% at 107 pmol/L, and 12.2% at
53.5 pmol/L, with a mean of 7% over the range, (n=10).
The inter-assay coefficient was 11.9% at 215 pmol/L, 15.7% at 107 pmol/L, 
and 16.15 at 53.5 pmoi/L, with a mean of 14.5% over the range, (n=1 1 ).
3.11 Recovery
Recoveries over a range of standards diluted in pooled normal human 
serum are shown in the table below:
Amount added Amount measured % recovered
215 pmol/L 250 1 1 0 %
107.5 140 118%
53.25 74 1 1 1 %
26.6 44 115%
13.3 28 1 1 2 %
6.7 2 0 104%
0 13
with a mean recovery of 1 1 1 % over the range.
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3.12 Paralle lism
A patient sample from a patient who later had an insulinoma removed, 
(courtesy Dr. S. Hampton), containing high endogenous proinsulin levels, 
serially diluted, produced a curve superimposible on the proinsulin 
standard curve for this assay. (Fig. 10).
3.13 Crossreactivitv
Crossreactivity with human insulin, bovine and porcine insulins, proinsulin 
intermediates and C-peptide was less than 0.64% in all cases (Fig. 11). 
The binding of intact proinsulin to the coating monoclonal antibody was 
reduced in the presence of insulin. (Fig. 12). The use of different 
temperatures and pH values did not improve the binding of proinsulin in 
the presence of insulin.
3.14 Normal range
Blood samples taken from sixteen normal non-obese volunteers 
demonstrated a mean fasting proinsulin level of 5.7 pmol/L, (range 2 0  -
1.67 pmol/L. + S.D. 5.88 pmol/L). Fasting blood samples were assayed 
from 6  Asian volunteers. One subject had a proinsulin level in this assay 
of approximately 400 pmol/L. This sample did not show parallelism when 
serially diluted or superimposed on the standard curve, and when tested 
in an established RIA was found to have a fasting proinsulin level within 
the normal range. The five remaining subjects had a mean fasting 
proinsulin level of 6.25 pmol/L (range 1.67 - 20 pmol/L).
3.15 Correlation with existing radioimmunoassay
Twenty fasting samples from lean normal subjects were measured in an 
established RIA, (Hampton etal, 1988), and in this ELISA. A correlation 
coefficient of r-0.767, (p<0.01) was obtained (Fig. 13).
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4. DISCUSSION
An immunosorbent enzyme-linked assay has been developed which is 
sensitive to 1.67 pmol/L, which is well below the normal fasting level as 
established in this assay. The normal fasting level shown in the assay agrees 
well with that demonstrated in other established assays measuring Intact 
proinsulin, (Sobey etal, 1989, Hartling et at, 1986). The assay is reliable and 
quick to perform, with reproducible results.
Problems were experienced in getting the level of background colour on the 
plate down to an acceptable amount. Since the assay was required to be very 
sensitive, non specific binding was unacceptable but was hard to eradicate 
whilst maintaining speed and good specific binding of the proinsulin. The use 
of a blocking stage, most effective with gelatine as the protein blocking agent, 
and the purification of the antibodies used, helped to reduce the non specific 
binding to acceptably low levels whilst maintaining a good standard curve. 
Blocking proteins can interfere with the binding of the antigen to the coating 
antibody by sheer size, particularly in the case of small biological antigens such 
as proinsulin, or by changing the configuration or binding properties of the 
molecules involved.
The fasting sample taken from a female Asian subject showed a very high level 
of proinsulin in the assay. The sampie did not demonstrate parallelism with the 
standard curve, and five other samples from Asian subjects assayed within the 
normal fasting range. ELISA is prone to interference from varying 
concentrations of different unidentified proteins in the blood. Had the high 
result been measured proinsulin, the sample would have run out parallel to the 
standard curve.
The final combination of antibodies selected provided an assay which is 
specific for intact proinsulin. It had been projected to use a monoclonal
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antibody to C-peptide as the antibody recognizing the serum proinsulin, but the 
only monoclonal developed in the available time did not work effectively in the 
assay. The insulin monoclonal selected was only effective as a coating 
antibody. When used as the first antibody to follow and bind the antigen, the 
assay was not successful. The polyclonal antibody will offer more binding sites 
than a monoclonal for the anti species specific labelled antibody to recognize. 
The assay is specific for intact proinsulin and crossreactivity with all other 
insulin containing molecules is negligible. However in the presence of insulin, 
binding of intact proinsulin to the insulin monoclonal antibody is reduced. (Fig 
12). It would seem that at fasting levels of both insulin and proinsulin there is 
little interference by insulin in the assay and that the assay would have 
application for measuring intact proinsulin in fasting samples, and some work 
done to date confirms this. However, further work is necessary to determine at 
what level insulin interferes with proinsulin binding at various proinsulin 
concentrations. The assay was run with buffers at varying pH values, and at 
different temperatures to assess the effect on Insulin and proinsulin binding in 
the assay, but these variables were not found to have a useful effect. Further 
and continuing investigations involves the use of a different monoclonal coating 
antibody to proinsulin. This antibody does not bind insulin but work so far 
suggests that the assay will measure proinsulin and its intermediates.
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CHAPTER 4.
Study: To determine Beta cell hormone levels In obese and 
normal weight subjects.
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1. INTRODUCTION
From the introduction to this project, it can been seen that there has been much 
interest and research into the circulating levels of proinsulin and its conversion 
intermediates in both normal and diabetic subjects. Assays have been 
developed to measure these circulating hormones using the relatively new 
monoclonal antibody technology. Although the relationship of obesity to 
diabetes has been researched for some time, to date little work has been 
published on proinsulin and its intermediates in obese subjects. Temple et al, 
(1988), found that basal intact proinsulin and 32,33 split proinsulin were higher 
in obese subject groups than in non obese groups, both in non insulin 
dependent diabetes mellitus, (NIDDM), and in normal subjects. The 
percentage of proinsulin-like molecules of the insulin containing molecules was 
also raised in the obese groups of both NIDDM and normal subjects. 
Concentrations of 65,66 split proinsulin were too low in this study to identify 
differences between groups.
This present study was designed as a pilot study to investigate levels of 
immunoreactive proinsulin together with des 64,65 proinsulin intermediate 
(PPF) in normal and obese subjects. The study investigated the p-cell 
response to a test meal in six normal and six control non obese subjects, 
matched for age and sex. It proved quite difficult to recruit obese subjects from 
the normal population who were prepared to take part for the sake of the study. 
Some people approached were reluctant to discuss their weight, although there 
was a lot of interest from overweight people who mistakenly thought the study 
would offer a magic cure for fatness. These obese volunteers were recruited by 
word of mouth rather than through hospital clinics, as subjects with no previous 
history of blood sugar regulation abnormalities were required. All twelve
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volunteers were healthy individuals in employment, with no known illnesses, 
and no continuous medications. The women were not pregnant. The study 
was designed to exclude as far as possible all factors which could affect 
differences in proinsulin levels in the two groups except obesity.
A generalised survey of the normal diet of the volunteers was advisable, as the 
study was trying to estimate the effects of food intake on the circulating levels of 
hormones affecting glucose levels in the blood. It was beyond the scope of this 
study to carry out a detailed assessment of the volunteer’s diet or to Interpret the 
findings of such an assessment or to comment on its relevance. It had proved 
difficult to recruit obese volunteers from the normal population who were not 
involved in prior medical studies relevant to their weight or blood glucose 
regulation. For this reason, volunteer participation in terms of time and effort 
involved was kept as undemanding as possible to maximise acceptability and 
hopefully to prevent volunteers dropping out. Restrictions of time and the field 
of knowledge being explored through this study precluded the area of diet 
being further investigated, but some general comments are noted, and may be 
of interest for further work.
Measurements of blood glucose, immunoreactive insulin (IMI) and 
immunoreactive C-peptide (IMGP) were made as well as PPF.
C-peptide is produced in equimolar amounts to insulin, but has a longer 
circulating half life. It is therefore a useful indicator of endogenous insulin in 
the presence of exogenous insulin, and measurements can be helpful in cases 
of hypoglycaemia if unwarranted injection of insulin is indicated. For the 
purpose of this study, it was measured as part of the complete profile of the 
blood glucose regulation hormones in both groups.
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2. THE STUDY
2.1 Study Design
The six obese volunteers recruited had a body mass index greater than 
30. Body mass index is arrived at by dividing the weight of the person in 
kilograms by the height in metres squared. They were healthy people who 
were not being treated on a continuing basis for any known medical 
problems, and who had no past history of blood sugar regulation 
abnormalities. They were matched for age and sex with six normal 
weight volunteers as controls. An estimation was made of the normal diet 
and alcohol intake of the volunteers. They were asked if they smoked 
and if there was any history of diabetes in the immediate family. They 
were asked to eat a controlled evening meal on the night before the study, 
not later than 9 pm, and not drink any alcohol.
It has been reported that the glycaemic index of carbohydrate in an 
evening meal can affect the glycaemic response to breakfast the following 
morning, even if the nutrient value of the evening meal does not vary, 
(Wolever et al, 1988). Volunteers were therefore asked to eat a small 
evening meal with a choice of protein foods and vegetables and a small 
amount of bread or potatoes, (high glycaemic index foods) to standardise 
the meal and allow for a possible variable. Volunteers were asked to 
report for the study in the morning without eating or drinking anything 
except a glass of water. The breakfast test meal was chosen to elicit a 
good glycaemic response. It contain 28g fat, 16g carbohydrate and 5g 
protein. White bread and cereal were included to limit fibre content and 
speed absorption.
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The study was carried out at the Investigation Unit at St. Luke's Hospital, 
Guildford.
Due to pressure of space at the unit, and also because of the rapidity of 
sampling and the necessity of handling the samples immediately, the 
volunteers attended the unit in batches of three.
Blood samples were taken before the test meal was eaten, and at regular 
intervals afterwards. The samples were collected in lithium heparin 
tubes, centrifuged at once, the plasma being pipetted off and frozen in 
aliquots immediately at -20°C. A small sample of whole blood was 
collected in fluoride oxalate tubes for blood glucose assay.
Permission for the study was obtained from the ethical committees of both 
the hospital and the University. Volunteers were given prior written 
information on their part in the study, including background information on 
proinsulin and the reasons for carrying out the study. They signed 
informed consent forms for the study. Written instructions were also given 
and explained before the study on the dietary requirements for 
participation in the study.
2.2 instructions to volunteers
They were asked to eat a restricted carbohydrate diet in the 24 hours 
before the study. The evening meal was to consist of ham, fish or eggs, 
with salad or vegetables, fruit or a yoghurt, one bread roll, tea or coffee but 
no alcohol. It was to be completed before 9 pm and nothing to be 
ingested thereafter. Volunteers were asked to eat or drink nothing before 
arriving for the study. They were told that the study results would indicate 
if they had eaten that morning.
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2.3 Study procedure
On arrival, all the volunteers were weighed and measured. An indwelling 
catheter was inserted in a branch of the cephalic vein in the back of the 
hand, and 1 2  ml blood samples taken at - 1 0  and zero minutes before the 
test meal. This was the most acceptable method of sampling over a 
period of four hours.
The volunteers were given a meal of rice crispies, milk, sugar, orange 
juice, toast, butter and marmalade, with tea or coffee, all weighed 
amounts. The meal was to be all eaten, and finished in 15 min.
Regular blood samples were taken at 15, 30, 45, 60, 75, 90, 120, 150, 
180, 210 and 240 min after the meal. Volunteers could drink water as 
required throughout the study. Samples were processed, labelled and 
frozen as collected. Fluoride oxalate tubes were filled with whole blood 
for assay for blood glucose.
2.4 Assay methods
Measurements of IMI and IMCP were carried out using antiserum 
produced by Dr. S. Hampton, School of Biological Sciences, University of 
Surrey. The assays were designed for the measurement of the 
unextracted serum.
To measure IMI, standards in the range 2 0 0  -3.13 mU/L and zero the 
samples were incubated in plastic LP3 tubes with guinea pig anti insulin 
antiserum, initial dilution 1:10,000 and incubated for 24 hours at 4°C. 
Radiolabelled insulin tracer was added to the tubes and incubated for a 
further 24 hours. The isotope used was iodine 125. Separation is 
achieved with donkey anti guinea pig antiserum in a polyethylene glycol 
solution. The tubes were centrifuged at 3000g for 30 min and the
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supernatant pipetted off. The tubes were then counted on a gamma 
counter. Protocol for this assay is summarised in Table 1 .
To measure IMCP, standard in the range 8  - 0.25 ng/ml and zero the 
samples were incubated with sheep anti C-peptide antiserum at an initial 
dilution 1:1500 and incubated as the insulin assay above. Labelled C- 
peptide tracer was added to the tubes and incubated as above. Donkey 
anti sheep antiserum was used to achieve separation. The protocol is 
summarised in Table 2 .
Measurements for PPF were carried out using the radioimmunoassay 
developed in this department, (Hampton et al 1988). This assay 
measures intact proinsulin and 65,66 split and 64,65 des proinsulin, with 
only 5% cross reactivity with 32,33 split proinsulin. Samples and 
standards in the range 430 - 3.313 pmol/L and zero were incubated with 
sheep anti proinsulin antiserum initial dilution 1:750 and incubated for 24 
hours at 4°C. Labelled proinsulin tracer was added and incubated 
overnight at 4°C. Phase separation was achieved with donkey anti 
sheep antiserum at an Initial dilution 1:16 in normal carrier serum and 
polyethylene glycol solution, incubated for 2  hours. The tubes were 
centrifuged at 1600g for 30 min, aspirated and counted on a gamma 
counter. This protocol is summarised in Table 3.
Crossreactivities for all these assays are shown in Table 4.
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TABLE 1. Protocol for Insulin Radioimmunoassay
Day 1 Day 2 Day 3
Tube
Total
Buffer
W
Antiserum
Hi
standard 
Sample or CSS 
W
Label
pi
100
NPGS Dab 
pi pi
4%
PEG
Reagent NSB 350 - 50 100 100 100 700
Zero 250 100 50 100 100 100 700
Standard 250 100 50 100 100 100 700
Test Serum 
NSB 350 50 100 100 100 700
Test Serum 250 100 50 100 100 100 700
TABLE 2. Protocol for C-oeotide Radioimmunoa<5say
Day 1 Day 2 Day 3
Tube
Total
Buffer
W
Antiserum
Hi
Standard 
Sample or CSS 
pi
Label
pi
100
NPGS Dab 
pi pi
4%
PEG
Reagent NSB 100 - 100 100 100 100 400
Zero 100 100 100 100 100 400
Standard 100 100 100 100 100 400
Test Serum 
NSB 100 100 100 100 100 400
Test Serum 100 100 100 100 100 400
100
TABLE 3. Protocol tor Proinsulin Radioimmunoassay
Day 1 Day 2 Day 3
Tube Buffer Antiserum standard Label NPGS Dab 4%
Sample or CSS PEG
pi pi pi pi pi piTotal 100
Reagent NSB 300 - 200 100 100 100 800
Zero 200 100 200 100 100 100 800
Standard 200 100 200 100 100 100 800
Test Serum
NSB 300 200 100 100 100 800
Test Serum 200 100 200 100 100 100 800
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3. RESULTS
3.1. S tgtjstloaLAngiysi^
Analysis of the results was performed using Student's t-test for paired and 
unpaired (two tailed) data. P values of 0.05 were accepted as statistically 
significant.
3.2. Study procedure
All subjects recruited attended for the study as arranged. Instructions 
concerning the evening meal prior to the study, and the overnight fast 
were understood, and subjects confirmed that they had followed the 
printed study plan. All subjects finished the test meal within 15-20 
minutes of the zero timepoint.
3.3. Body mass index (BMI)
On the morning of the study the normal subjects, age range 25 - 48 years, 
had a BMI range from 20.5 to 24.2 kg/m2  (mean 23.2 + 2.4 kg/m2). The 
obese subjects, age range 21 - 49 years, had a BMI range from 31.1 to 54 
kg/m2 (39.4 + 7.7 kg/m2).
3.4 Normal diet estimations
All subjects were aware of healthy dietary requirements, calorific values of 
food groups etc., and with possibly one exception, were honest about their 
normal food intake.
Normal group; All subjects ate a healthy and normal diet with one subject 
being a vegetarian. Breakfasts were cereals, toast, tea, coffee and 
vegetable fats. Lunches were sandwiches, fruit, yoghurt, occasional 
chocolate bars and hot drinks. Main meals were well balanced, with 
protein, vegetables, pasta, fruit and yoghurts, with roast dinners and richer
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puddings at weekends. Most subjects used brown bread, vegetable 
margarine, controlled sugar and salt intake and snacked only 
occasionally. Average alcohol consumption was about 15 units a week, 
(one subject 35 units) and only one subject smoked. Frying of food was 
unusual.
Obese group: Reported diets were more varied in this group. One
subject suggested an Improbably low calorie diet. Most admitted to 
eating too much, with the bigger subjects eating a lot too much. One 
subject had sweet binges alternating with half hearted dieting phases. All 
were aware that weight could be lost if they ate less. The largest female 
subject ate a large number of calories daily, mainly as snack food and 
was unable to control her intake, even though surgery had been resorted 
to.
3.5 Assay results
There were no significant differences in the IMI and IMCP levels between 
the two groups (Figs. 1 and 2 ). Basal insulin levels were 33.5 + 9.4 
pmol/L (mean + SEM) in normal subjects, and 51 + 17.7 pmol/L in the 
obese group. Basal C-peptide levels were 54 pmol/L in the obese group 
and 34.3 pmol/L in the normal group, with wide variation between 
subjects in the obese group.
Fasting glucose levels were only significantly different between the obese 
and normal groups at the 180 minute timepoint, (p<0.01), (Fig. 3). Levels 
of proinsulin, including des 64,65 proinsuiin fragment were higher in the 
obese group than the normal group but the difference was not statistically 
significant, (Fig. 4).
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The obese group had a peak level of 88.2? 45 pmol/L at the 120 minute 
timepoint. The normal subjects plateaued between 90 - 150 minutes at a 
mean level of 28.9 + 6.4 pmol/L.
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Crossreactivities of the IMI, IMCP and PPF assays are shown in Table 3. 
The sensitivities of the IMI, IMCP and PPF radioimmunoassays were 12, 
19 and 6.7 pmol/L respectively (2 standard deviations from zero). 
Interassay coefficient of variation was less than 10% for all three assays. 
One normal subject showed results at variance with the mean of the 
normal group for levels of blood glucose, IMI and PPF, although the C- 
peptide level was not different from the rest of the group.
The levels of these hormones in this subject are shown against the mean 
of the levels of the other five normal subjects in Figs. 5 - 7. The PPF level 
in this subject peaked at 6 6  pmol/L at 90 minutes, starting to rise at the 30 
minute timepoint. Blood glucose was very high and stayed high for 
longer, and IMI levels were also high, compared with the mean of the 
normal group.
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4. DISCUSSION
Although obesity Is usually associated with hyperinsulinaemia, (Peiras et al, 
1989), the observed IMI levels in this study were similar in both groups, with 
basal levels in the obese group being higher than the normal group, but not 
significantly so. This may be because of the crossreactivity with proinsulin and 
proinsulin fragments in the insulin assay. IMCP levels were higher in the obese 
group, but there was a large variation between individuals in the group, and the 
sample size was small.
All assays used in the study have been tested for crossreactivity, (Table 3). The 
insulin and C-peptide assays crossreact to a greater extent with proinsulin 
fragments than with intact proinsulin. Certain disease states have elevated 
levels of proinsulin fragments (Temple et al, 1989), and the crossreactivities of 
assays is to be taken into account when interpreting the results of any clinical 
studies.
The normal subject with high IMI, glucose and PPF levels was later revealed as 
having a close relative with non insulin dependent diabetes. It is possible that 
the elevated levels of proinsulin plus proinsulin intermediate des 64,65, 
together with an abnormal response to glucose intake may be an indication of a 
prediabetic state in this subject. Further studies are in progress to investigate 
this proposition involving maturity onset diabetics and their offspring, and these 
studies may help to determine whether results from this subject are significant. 
From Fig. 4, normal subjects have lower PPF levels than obese subjects, 
although the differences are not significant. The obese group exhibited a wide 
range of PPF levels. Within the group there were two distinct subgroups, and 
although the study was small, it is possible that these differences may have 
been related to body fat distribution. The radioimmunoassay used to measure 
intact and des 64.65 proinsulins together crossreacts only slightly with des
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Arg31, Arg32 proinsulin intermediate which has been shown to be the major 
circulating proinsulin-like molecule in humans (Gray et al, 1987, Sobey et a;l, 
1989). Normal subjects release very little des 64,65 proinsulin intermediate 
(Temple etal, 1989). It may be that some obese subjects release higher levels 
of des 64,65 proinsulin due to incomplete processing of the proinsulin molecule 
by an over stressed pancreas.
In practical terms the study proceeded smoothly. There were no problems with 
non attendance, and all subjects were very co-operative. No problems were 
encountered with sampling, or with processing or assaying the samples. It is 
interesting to note that participation in the study triggered some conscious 
weight loss among the obese subjects. One male subject lost more than 31 
kilograms, reducing a BMI of 39 kg/m^ to 28 kg/m^. It would be interesting to 
compare results from subjects taking part in a similar study before an after such 
a significant weight loss, although difficult to arrange.
115
CONCLUSION
At the outset of this project the development of an assay specific for human 
intact proinsulin was considered to be worthwhile as a tool in the investigation of 
abnormalities of g cell hormone production and release. There continues to be 
interest in the circulating levels of insulin, proinsulin and the intermediate forms of 
proinsuiin. Temple et al, (1990), report that the level of circulating insulin in 
NIDDM subjects measured in specific Immunoradiometric assay (IRMA) is only 
38% of that measured by RIA, which measures the sum of the immunoreactive 
insulin-iike molecules. They conclude that there may be some confusion in the 
literature over the status of Insulin and proinsuiin in NIDDM subjects.
It has been shown that the concentrations of 65,66 split proinsuiin are very 
low in both normal and NIDDM subjects (Sobey et al, 1989). It has also been 
shown that proinsuiin-like molecules in plasma in normal subjects account for only 
10-20% of the immunological insulin-iike molecules in plasma, (Yoshioka et al, 
1988). Morris et al, (1993) report total immunoreactive proinsuiin as 14% of total 
immunoreactive Insuiin-like molecules in fasting plasma from NIDDM patients. It 
has also been reported by Temple et al, (1989) that fasting levels of intact 
proinsuiin are 2.4 pmoi/L in normal subjects and 7.1 pmoi/L in NIDDM subjects, 
and fasting levels of 32,33 split proinsuiin are 8.7 pmoi/L in normal subjects and 
19.2 pmol/L in NIDDM subjects. Therefore the majority of circulating proinsuiin- 
iike molecules in both groups is 32/33 split proinsuiin, which is in agreement with 
the literature, (Gray etal, 1984, Sobey etal, 1989, Nagi etal, 1990). Although the 
literature reports these fragments as split forms, it has been shown that circulating 
proinsuiin intermediates are in fact the des 31,32 and des 64,65 forms (Given etal, 
1985).
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A recently published amplified sandwich ELISA assay (Dhahir et al, 1992) 
measures intact and.both des proinsulins and gives a level for total circulating 
proinsuiin, with a fasting level of 4.73 pmoi/L in healthy fasting subjects. This 
assay uses a polyclonal antibody to proinsuiin as the first primary antibody, and a 
monoclonal antibody to C-peptide as the second primary antibody, (prepared by 
Novo Labs Ltd., Denmark). This project had planned to use a C-peptide 
monoclonal antibody in an ELISA for proinsuiin as detailed earlier, but it did not 
prove possible to develop such an antibody in the time available. The problems 
with the development of a monoclonal antibody to C-peptide may be due to its 
small size and tertiary structure which combine to make it a poor immunogen. 
There were also problems with establishing stable antibody-producing clones. 
The antibody produced for this project was not suitable for use in the ELISA as 
planned, using an insulin monoclonal antibody as the first primary antibody. 
However it is possible to produce such an antibody for use in ELISA , (Dhahir etal, 
1992) and further work might prove rewarding. An assay for total immunoreactive 
proinsuiin has been reported using C-peptide and insulin monoclonal antibody 
(Novo Nordisk) by Morris etal, (1993). Fasting proinsuiin was measured as 6.7 
pmol/L in NIDDM subjects.
Although the assay developed in this project for intact proinsuiin used a 
monoclonal antibody which did not crossreact with the intermediate forms of 
proinsuiin, the assay was not accurate in the presence of levels of circulating 
insulin likely to be found in all but fasted subjects. It is possible that a monoclonal 
antibody to proinsuiin can be developed that will allow the measurement of intact 
proinsuiin alone. Restrictions of time and finance in this project did not allow
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further monoclonal antibody development work, and so far monoclonal antibodies 
available to us from other sources have not provided a suitable ELISA reagent.
The results from the clinical study investigating the levels of p cell hormones 
in a group of healthy obese subjects and a group of control subjects matched for 
age and sex were informative. The basal immunoreactive insulin levels tended to 
be lower in the non-obese group, but the differences were not statistically 
significant. This agrees with the work of Temple et al, (1989). Levels of proinsuiin 
together with des 64,65 proinsuiin as measured by RIA were higher in the obese 
subjects but not significantly. Temple etal, (1989), measured intact proinsuiin in 
groups of obese and non-obese subjects as controls to obese and non-obese 
NIDDM subjects. Their results are also higher in the obese group, but they do not 
report the statistical significance of their findings.
One subject in the study for this project in the normal group had results at 
variance with the rest of the group, (Chapter 4, Figs. 5-7). This subject had a first 
degree relative (father) with non-insuiin dependent diabetes. This result suggests 
that further investigations into pcell hormone levels in subjects with either insulin 
or non-insuiin dependent diabetes might be informative, possibly identifying 
subjects at particular risk. For ail such studies assays which measure intact 
proinsuiin or are specific for insulin or the intermediate forms of proinsuiin would be 
very useful.
In conclusion, although the aims of this project were not fulfilled as outlined 
at the beginning, nevertheless the work has led to some interesting results and 
suggestions for future progress. Continuing development to produce specific 
assays for intact proinsuiin, proinsuiin intermediates and specific insulin would be
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worthwhile, and such work is in progress at the present time. Further studies couid 
heip elucidate the role of obesity in the biochemistry leading to the development of 
diabetes. The results from the study have led to studies measuring circulating 
levels of p ceil hormones in groups of subjects with first degree relatives with 
diabetes, and with diabetic mothers and newborn infants.
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